CANCER IMMUNOTHERAPY: TARGETED CELLULAR VEHICLE-MEDIATED IMMUNOGENE THERAPY AND DENDRITIC CELL-BASED VACCINE by YOVITA IDA PURWANTI
CANCER IMMUNOTHERAPY: TARGETED 
CELLULAR VEHICLE-MEDIATED 

















CANCER IMMUNOTHERAPY: TARGETED 
CELLULAR VEHICLE-MEDIATED 
IMMUNOGENE THERAPY AND DENDRITIC 
CELL-BASED VACCINE 
 
YOVITA IDA PURWANTI 
(B.Sc.Hons., National University of Singapore) 
 
 
A THESIS SUBMITTED 




DEPARTMENT OF BIOLOGICAL SCIENCES 
NATIONAL UNIVERSITY OF SINGAPORE 
& 





I hereby declare that the thesis is my original work and it has been written by 
me in its entirety. I have duly acknowledged all the sources of information 
which have been used in the thesis. 








Yovita Ida Purwanti 





I would like to express my gratitude to my supervisor A/P Wang Shu for 
providing me the opportunity to work on this project. Thank you for your 
support and guidance which have allowed me to learn and make tremendous 
progress in my research and thinking abilities throughout my candidature. 
I would like to thank my past and present lab mates in IBN and DBS, NUS. I 
deeply appreciate all the help and advices I have received for my project. 
Special thanks to Tim and Lam for the fun, laughter and friendships that have 
made my lab life fruitful and memorable.  
I am grateful for my loving parents and sisters. Thank you for supporting my 
decision to embark on this journey and for the care and reliance that I can 
always turn to.  
I would also like to thank Alvin, Meirita, Elis, Budi, Sin Man, Yunika and all 
other good friends of mine whom I cannot possibly name one by one. I am 
grateful for all the encouragements which have motivated me a great deal 
throughout this PhD journey. 
Lastly, I would like to acknowledge the National University of Singapore and 
the Institute of Bioengineering and Nanotechnology for the opportunity and 
support granted to me to do a PhD.      
 
“Bless the Lord, O my soul, and do not forget all His benefits” 
 – Psalm 103:2  
ii 
 
Table of Contents 
 
ACKNOWLEDGEMENTS ....................................................................................................... I 
TABLE OF CONTENTS .......................................................................................................... II 
SUMMARY .............................................................................................................................. V 
LIST OF TABLES ................................................................................................................. VII 
LIST OF FIGURES ............................................................................................................... VIII 
LIST OF ABBREVIATIONS ................................................................................................... X 
LIST OF PUBLICATIONS ................................................................................................... XIII 
CHAPTER I: INTRODUCTION ............................................................................................... 1 
1.1 CANCER IMMUNOLOGY .............................................................................................. 2 
1.1.1 Tumor antigen recognition and presentation by dendritic cells ........................... 2 
1.1.1.1 Dendritic cells as professional antigen presenting cells ...................................... 2 
1.1.1.2 Tumor antigen presentation.................................................................................. 3 
1.1.1.3 Dendritic cells bridge the innate and adaptive immunities .................................. 5 
1.1.2 Cytotoxic T Lymphocytes: professional killers of immune system ........................ 6 
1.1.2.1 Activation of cytotoxic T lymphocytes .................................................................. 6 
1.1.2.2 Antitumor effects of cytotoxic T lymphocytes ....................................................... 7 
1.1.3 Tumor evasions of dendritic cells surveillance and cytotoxic T lymphocytes 
killing mechanisms ............................................................................................................ 8 
1.2 CANCER IMMUNOTHERAPY ...................................................................................... 10 
1.2.1 Stem cells as cellular delivery vehicle for cancer gene immunotherapy ............ 10 
1.2.1.1 Stem cell candidates for immunotherapy ............................................................ 10 
1.2.1.2 Stem cell delivery of cytokine for cancer immunotherapy .................................. 12 
1.2.1.3 Immunotherapy via in situ antibodies delivery by stem cells ............................. 13 
1.2.2 Dendritic cell-based vaccinations ...................................................................... 15 
1.2.2.1 Dendritic cells as an excellent candidate for developing therapeutic vaccines 
against cancer ................................................................................................................. 15 
1.2.2.2 Loading dendritic cells with tumor-specific antigens ......................................... 16 
1.2.3 Other approaches ............................................................................................... 18 
1.2.3.1 Adoptive T cells for cancer therapy .................................................................... 18 
1.2.3.2 Genetic engineering of T cells ............................................................................ 19 
1.2.4 Challenges in cancer immunotherapy ................................................................ 20 
1.3 PURPOSES AND MOTIVATIONS.................................................................................. 22 
CHAPTER II: ANTITUMOR EFFECTS OF CD40 LIGAND-EXPRESSING 
ENDOTHELIAL PROGENITOR CELLS DERIVED FROM HUMAN IPS CELLS IN A 
METASTATIC BREAST CANCER MODEL ........................................................................ 24 
2.1 INTRODUCTION ........................................................................................................ 25 
2.1.1 EPCs ................................................................................................................... 25 
2.1.1.1 Definition, Sources and characterization ........................................................... 25 
2.1.1.2 EPCs gene therapy strategies ............................................................................. 26 
2.1.1.2.1 Suicide gene therapy .................................................................................. 26 
2.1.1.2.2 Antiangiogenic therapy .............................................................................. 27 
2.1.1.2.3 Immunotherapy .......................................................................................... 28 
2.1.2 CD40 ligand ....................................................................................................... 29 
2.1.3 Induced pluripotent stem cells ............................................................................ 30 
iii 
 
2.1.4 Objective and Aim of Study ................................................................................ 31 
2.2 MATERIAL AND METHODS ....................................................................................... 33 
2.2.1 Cell culture ......................................................................................................... 33 
2.2.2 Stromal-based EPC derivation method .............................................................. 35 
2.2.2.1 OP9 co-culture ................................................................................................... 35 
2.2.2.2 M2-10B4 co-culture ............................................................................................ 36 
2.2.3 Non-stromal-based EPC derivation method ....................................................... 36 
2.2.3.1 2-D culture ......................................................................................................... 36 
2.2.3.2 Embryoid bodies method .................................................................................... 37 
2.2.4 Characterization of EPCs ................................................................................... 38 
2.2.4.1 Flow cytometry ................................................................................................... 38 
2.2.4.2 Immunostaining .................................................................................................. 38 
2.2.4.3 Tubulogenesis assay ........................................................................................... 38 
2.2.4.4 DiI-Ac-LDL assay ............................................................................................... 39 
2.2.5 Baculoviral vector preparation .......................................................................... 39 
2.2.6 Animal studies .................................................................................................... 41 
2.2.6.1 Animals ............................................................................................................... 41 
2.2.6.2 Dual in vivo imaging system ............................................................................... 41 
2.2.6.3 Biodistribution of EPCs in intracranial 2M1 tumor model ................................ 42 
2.2.6.4 Therapeutic studies of EPCs ............................................................................... 42 
2.2.7 Histology ............................................................................................................ 43 
2.2.8 Statistical analyses ............................................................................................. 43 
2.3 RESULTS .................................................................................................................. 44 
2.3.1 Generation of EPCs from Human Pluripotent Stem Cells .................................. 44 
2.3.1.1 OP9 co-culture method ....................................................................................... 44 
2.3.1.2 M2-10B4 co-culture method ............................................................................... 47 
2.3.1.3 Non-stromal 2-D differentiation method ............................................................ 51 
2.3.1.4 Human iPS cell-derived EPCs via embryoid bodies formation .......................... 53 
2.3.2 Tumor tropism of iPS-EPCs ............................................................................... 58 
2.3.2.1 Homing of hPSC-EPCs to 4T1-luc orthotopic breast cancer model .................. 58 
2.3.2.2 Homing of iPS-EPCs to breast cancer lung metastasis model ........................... 63 
2.3.2.3 Tumor tropism of iPS-EPCs to 2M1 invasive glioma model .............................. 65 
2.3.3 Effects of iPS-EPCs on tumor development and metastasis ............................... 67 
2.3.4 Genetic modification of EPCs ............................................................................ 72 
2.3.5 EPCs therapeutic effects ..................................................................................... 74 
2.3.5.1 iPS-EPC expressing CD40L impede tumor development in a breast cancer lung 
metastasis model .............................................................................................................. 74 
2.3.5.2 iPS-EPCs expressing HSV-tk .............................................................................. 76 
2.3.5.3 iPS-EPCs expressing Isthmin ............................................................................. 77 
2.4 DISCUSSION ............................................................................................................. 80 
2.4.1 Derivation of EPCs ............................................................................................. 80 
2.4.2 Tumor tropism of iPS-EPCs ............................................................................... 85 
2.4.3 Effect of iPS-EPCs in cancer growth and metastasis ......................................... 86 
2.4.4 Immunotherapy of EPCs using CD40L .............................................................. 87 
2.4.5 Challenges and future direction ......................................................................... 90 
CHAPTER III: TARGETED CANCER THERAPY USING CYTOTOXIC T 
LYMPHOCYTES ACTIVATED BY DENDRITIC CELLS PULSED WITH CANCER 
STEM CELL-LIKE CELLS ..................................................................................................... 94 
3.1 INTRODUCTION ........................................................................................................ 95 
3.1.1 Cancer stem cells ................................................................................................ 95 
3.1.2 Objective ............................................................................................................. 96 
iv 
 
3.2 MATERIAL AND METHODS ....................................................................................... 99 
3.2.1 DCs and naïve T cells derivation from PBMC ................................................... 99 
3.2.2 Tumor lysate preparation ................................................................................... 99 
3.2.3 DCs pulsing with tumor lysate and maturation ................................................ 100 
3.2.4 CTL stimulation and expansion ........................................................................ 100 
3.2.5 Flow cytometry ................................................................................................. 100 
3.2.6 ELISPOT .......................................................................................................... 101 
3.2.7 Statistical analyses ........................................................................................... 102 
3.3 RESULTS ................................................................................................................ 102 
3.3.1 DCs derivation and characterization ............................................................... 102 
3.3.2 Naïve T cells selection and characterization .................................................... 107 
3.3.3 IFNγ production of CTL activated by CSC-like-CRC-pulsed DC..................... 109 
3.3.4 IFNγ production of CTL activated by CSC-like-glioma-pulsed DC ................. 110 
3.4 DISCUSSION ........................................................................................................... 112 
3.4.1 DC differentiation and characterization .......................................................... 112 
3.4.2 Activated CTLs display appropriate co-stimulatory molecules and antigen-
specific targeting ........................................................................................................... 114 
3.5 FUTURE DIRECTION ............................................................................................... 116 
CHAPTER IV: CONCLUSION ............................................................................................. 119 
CHAPTER V: BIBLIOGRAPHY .......................................................................................... 124 





Cancer immunotherapies have treated many cancer patients and improved 
their quality of life. In spite of their clinical effects, the available treatments 
using cytokines and antibodies are still hindered by their toxic effects, half-life 
and efficacies. In this project, we are interested in the developments of 
immunotherapies using the stem cell vehicles to deliver immunogene products 
and the dendritic cell (DC)-based vaccination approach. 
Targeted immuno-gene therapy approach using the stem cell delivery 
vehicle is based on the inherent tumor tropism of stem cells. Endothelial 
progenitor cells (EPCs) is particularly attractive, not only due to their intrinsic 
tumor tropism but also their involvement in cancer angiogenesis. However, 
collecting a sufficient amount of EPCs is one of the challenging issues critical 
to achieving effective clinical translation of this new approach. In this study, 
we sought to explore whether human induced pluripotent stem (iPS) cells 
could be used as a reliable and accessible cell source to generate uniform 
human EPCs with cancer gene therapy potential. We showed that by using an 




 EPCs could be efficiently 
derived from human iPS cells. The generated EPCs expressed endothelial 
markers such as CD31, Flk1 and VE-cadherin but not the CD45 hematopoietic 
marker. Subsequently, we showed that intravenously injected iPS cell-derived 
EPCs migrated towards orthotopic and lung metastatic tumors in the mouse 
4T1 breast cancer model, and that injection of the EPCs alone did not escalate 
tumor growth and metastatic progression. Most importantly, the systemic 
injection of EPCs transduced with baculovirus encoding the potent DC co-
vi 
 
stimulatory molecule CD40 ligand could impede tumor growth, leading to 
prolonged survival of the tumor-bearing mice. Therefore, our findings suggest 
that human iPS cell-derived EPCs could potentially serve as tumor-targeted 
cellular vehicles for anticancer gene immunotherapy. 
Despite their proven effectiveness in reducing the tumor burden, most 
of the available cancer treatments, including chemotherapy and radiation 
therapy, fail in eradicating cancer stem cells (CSCs). With their capability for 
self-renewal and differentiation, CSCs are capable of re-establishing the tumor 
mass, resulting in the relapse of tumors in patients. By utilizing baculovirus-
zinc-finger technology, we have reprogrammed human glioma and colorectal 
cancer cell lines into CSC-like cells. We generated whole tumor lysates from 
these enriched CSCs using freeze-thaw-cycles and used them to pulse PBMC-
derived DCs. We showed that we could obtain sufficient functional DCs that 
were capable of stimulating naïve T cells into cytotoxic T lymphocytes 
(CTLs). The stimulated CTLs were capable of producing IFNγ cytokine in a 
CSC-like antigen-specific manner. Our findings suggest that DC-based 
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1.1 Cancer immunology 
Cancer is a pathological condition affecting people regardless of their age and 
gender, and is one of the leading causes of death worldwide
1
. While vast 
amounts of research have been conducted to treat and improve the health and 
life expectancy of cancer patients, an ideal cure has not yet been found. 
Though cancer seems formidable, our own body’s immune system is built 
with the capability to recognize and destroy malignantly transformed 
autologous cells. Dendritic cells (DCs), the body’s designated professional 
antigen presenting cells (APCs), play a critical role in recognizing tumor cells 
and activating arrays of immune effectors to eliminate them. One such effector 
that has a central role in eradicating tumor cells is cytotoxic T lymphocytes 
(CTLs). The intricate mechanisms which control how our immune system 
recognizes and kills the cancerous cells, as well as the evolving mechanisms 
of the tumor to evade this system, will be discussed briefly below. 
1.1.1 Tumor antigen recognition and presentation by dendritic cells 
1.1.1.1 Dendritic cells as professional antigen presenting cells 
Macrophages and dendritic cells in the innate immune system possess 
phagocytic capability and antigen recognition ability. These cells use innate 
non-clonal receptors, such as Toll-like receptors, lectins, scavenger receptors, 
FC receptors and other pattern recognition receptors (PRRs) to perceive and 
recognize different types of antigens
2, 3
. However, unlike macrophages which 
have antimicrobial and scavenging functions, DCs are inefficient in destroying 
the antigen-expressing cells
2, 3
. The phagocytic activities of DCs are designed 
to facilitate antigen processing and presentation to the T cells for the initiation 
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of antigen-specific adaptive immune response. As professional APCs, DCs 
exist in two functional states: the immature and mature states
4
. Immature DCs 
are adept at acquiring the antigens whereas the mature DCs are responsible for 
stimulating T cells by presenting the acquired antigens.  
Tumor cells express proteins or peptides which are considered foreign 
by the immune system of the body. Tumor development is associated with the 
chaotic proliferation of viable tumor cells as well as disordered tumor cell 
deaths in the form of apoptosis and necrosis. Moreover, tumor cells are known 
to secrete soluble proteins and exosomes which carry antigens
5
. The immature 
DCs in the periphery are actively engulfing antigens (both self and foreign) via 
endocytic processes including phagocytosis, pinocytosis and clathrin-mediated 
endocytosis
4
. Thus, tumor antigens may be transferred into the dendritic cells 
via phagocytosis of apoptotic or necrotic tumor cells, pinocytosis of soluble 
antigens or capture of exosomes. 
Upon tumor antigen encounter, DCs undergo maturation, upregulate 
chemokine receptors to facilitate migration into the lymph nodes via the blood 
or lymph and increase their expression of co-stimulatory molecules for 
engaging T cells
2, 3, 6
. In the lymph nodes, their job is to properly present these 
tumor antigens to the adaptive immune effectors in the context of MHC 
(Major Histocompatibility Complex) to their cell surface. 
1.1.1.2 Tumor antigen presentation  
Antigen presentation is the process by which protein fragments are complexed 
with MHC products and posted to the surface of dendritic cells, resulting in 
the orchestration of immune responses repertoire. MHC molecules are 
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encoded by a large gene family that is located on chromosome 6 in humans
7
. 
MHC class I and II regions encode for genes which are involved in antigen 
presentation to T cells and hence control immune reactions against antigens 
such as, grafts acceptance/rejection and anti-tumor responses
7, 8
.  
In MHC I antigen presentation pathways, tumor antigens are acquired 
and presented in a process known as cross-presentation
3, 5
. The acquired tumor 
antigens will be targeted for destruction and proteolysis processes resulting in 
smaller peptides in the cytosol. Subsequently, these processed peptides are 
delivered and bound to the MHC class I molecules in the endoplasmic 
reticulum with the help of TAP (Transporter associated with Antigen 
Processing) proteins
9, 10
. Subsequently, these MHC-peptide complexes are 




MHC II molecules (HLA-DR, -DQ and -DP), unlike MHC I molecules 
that are expressed by all nucleated cells, are only found on APCs. Tumor 
antigen presentation by MHC II molecules expressed on the DCs triggers the 
activation of T helper cells (TH) via interaction with the CD4 receptor. The 
stimulation of TH cells results in the secretion of cytokines to boost the CTL 
responses and the production of antibodies by B cells
8, 11
. Upon tumor antigen 
recognition, which can be in the form of foreign nucleic acid, glycolipid, 
peptide or carbohydrate, the antigen-specific B cell will undergo clonal 
expansion, producing high affinity antibodies
12
. Thus, the presentation of 
tumor antigen-MHC complexes by APCs directs the activation of adaptive 
immune arsenals, both T and B cells, to kill the tumor cells. 
5 
 
1.1.1.3 Dendritic cells bridge the innate and adaptive immunities 
The components of innate immunity, which include APCs, natural killer (NK) 
cells and complement system, are quick in responding to danger signals given 
by the tumors. Although fast in its response, innate immunity is not powerful 
enough to eradicate the tumor cells. Activation, production and clonal 
expansion of tumor specific T cells and B cell antibodies are required to kill 
the tumor cells more effectively. The DCs play a central role in the cross-talks 
between adaptive and innate immunities.  
As the DCs uptake, process and present tumor antigens to activate the 
adaptive immune effectors, NK cells act as the first line of defense against the 
tumors
13
. The NK cells recognize neoplastic cells due to the down-regulation 
of MHC I expression (‘missing-self’ signal) and expression of NKG2d 
(‘induced-self’ signal) on these target cells13-15. Once activated, NK cells exert 
cytolytic effect on the target cells via perforin and granzymes production
14
. 
NK cells also secrete various cytokines such as IFNγ to help DC maturation16. 
Moreover, the killing of target cells by NK cells can enhance presentation of 
antigens from the apoptotic cells by DCs
17
. Consequently, the mature DCs will 
activate T cells via antigen presentation. In turn, the activated T cells produce 




Aside from presenting antigens, DCs also produce various cytokines 
that are important in regulating both innate and adaptive immune responses 
against tumors. One such cytokine is IL12, which has been shown to be an 
essential regulator for skewing toward TH1 responses. IL12 is also important 
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in further enhancing cytolytic activities of NK cells
14, 17, 19
. Thus, through the 
presentation of antigens, cell-cell interaction and cytokine production, DCs 
communicate with both arms of the immune system to ensure proper 
responses against cancer.  
1.1.2 Cytotoxic T Lymphocytes: professional killers of immune system 
1.1.2.1 Activation of cytotoxic T lymphocytes 
The adaptive immune cells, both B and T cells, are produced in the bone 
marrow. However, as the name implies, T cells undergo maturation in the 
thymus. T cells are segregated into different subtypes including CD8
+
 naïve T 





. These different T cell populations play different roles in the immune 
system. Memory T cells provide long-term immunity against previously 
encountered antigens. TH cells, mainly categorized into TH1 and TH2, provide 
signals in the form of direct cellular contact and cytokines to enhance both B 
and T cell responses
22
. TH1 cells produce cytokines such as IFNs and IL2 
cytokines to promote the CTL-mediated immune response
11, 22
. TH2 cells 
produce cytokines such as IL4 to enhance antibody production
11, 22
. However, 
the mechanism of tumor cell elimination relies largely on CD8
+
 CTLs. 
CTL activation is initiated when the CD8
+
 T cell receptor (TCR) 
recognizes the antigen peptide-MHC I complex on an APC which leads to T 
cell differentiation and extensive proliferation into CTLs
22, 23
. However, 
antigen recognition alone is insufficient to fully activate CTL. Interaction of 
co-stimulatory signals between APCs and T cells is needed to promote T cell 





For example, CD28 interaction with CD80 and CD86 on APCs is needed to 
stimulate T cell activation via amplification of the signals from TCR
11, 25
. The 
development of optimal CTL activation also requires survival signals provided 




1.1.2.2 Antitumor effects of cytotoxic T lymphocytes 
If DCs are the professional APCs, CTLs are the professional killers which can 
specifically target and eliminate malignant cells. CTLs inspect MHC I 
molecules that are found in all nucleated cells through the binding of CD8 
receptor
11
. MHC I gene products, which are designated as HLA (Human 
Leukocyte Antigen) -A, -B and -C, are encoded by different loci whereby each 
locus possesses extensive allelic variations
7
. The recognition of tumor antigens 
by CTLs is HLA restricted, in that CTLs and tumor cells must have the same 
HLA type for appropriate recognition
11
. 
When the cells expressing the antigen that has been reported by the 
DCs have been found, they will be targeted by CTLs for destruction. CTLs kill 
the target cells in a contact-dependent manner
22
. Upon target cell recognition, 
CTL granules are mobilized towards the target cells, followed by fusion of the 
granule membranes with the plasma membrane of the target cells. Exocytosis 
of the granule contents, which are the granzymes and perforin, into the target 
cells triggers cell lysis
22
. Apoptotic pathways can also be activated through the 
expression of the Fas ligand on the CTLs which engages the Fas (CD95) 
receptor on the target cell membrane
22
. CTLs also exert their antitumor effects 





.  Effective antigen-specific cytolysis which 
spares normal cells is the inherent characteristic of CTLs and has become the 
ultimate goal of cancer immunotherapies. Unfortunately, the current available 
treatments still evoke some degree of off-target toxic effects.  
Tumor tissues are often infiltrated with activated adaptive immune 
cells, indicating the presence of vigorous responses against cancer
26, 27
. 
Although adaptive immune effectors provide powerful antitumor effects, their 
activation requires time. Eventually, the interplay of innate and adaptive 
immune responses is important for fully-mounted immunity against cancer. 
When all the parts are serving their purposes well, tumor eradication will 
ensue. Unfortunately, in cancer patients, this is not the case.  
1.1.3 Tumor evasions of dendritic cells surveillance and cytotoxic T 
lymphocytes killing mechanisms  
Although the immune system is capable of recognizing and eliminating tumor 
cells, the inherent genetic instability of the latter frequently interferes with the 
development and function of immune responses
1, 24
. Progressive tumors often 
exhibit strategies that promote evasion from immune recognition and/or 
killing. These mechanisms include developing poor immunogenic properties 
to avoid proper presentation by DCs and to evade CTLs targeting, producing 
immunosuppressive cytokines and mediators, as well as piggybacking the pro-
inflammatory immune cells to render DCs and T cells tolerant.  
One mechanism to evade immune surveillance is to down-regulate the 
expressions of MHC I molecule so as to avoid CTLs inspection. Likewise, the 
NK cell activating ligands on the tumor cells are usually down-regulated too. 
9 
 




Another scenario by which tumor cells reduce immune stimulation is 
the induction of tolerogenic DCs. Indeed, a number of studies have reported 
that DCs are dysfunctional in cancer patients
30, 31
. The accumulation of 
tolerogenic DCs is attributed to the secretion of SDF-1 (Stromal-derived 
Factor-1) and IL6 by tumor cells
28, 32
. These DCs are defective in antigen 
presentation and further induce T and NK cells tolerance through the 
production of IL10 or TGFβ28, 33. 
Aside from SDF-1, IL10 and TGFβ, other immunosuppressive 
mediators which are abundant in tumor microenvironment include adenosine, 
prostaglandin E2 and Vascular Endothelial Growth Factor A (VEGF-A)
34
. 
These mediators promote angiogenesis via attraction of endothelial cells and 
favor stromal development by recruiting pro-inflammatory immune effectors 
(such as macrophages and complement components)
28, 35
. In addition, they 




 T cell subpopulation known as 
Tregs, which suppress CTL responses
28, 36
. Increased accumulation of Treg 
cells in many human malignancies, such as lung, head and neck, ovarian, 
stomach and skin cancer, is associated with poor prognosis for patients
28, 36
. 
Depletion of Tregs through the administration of anti-CTLA-4 antibody 
showed marked therapeutic effects in murine models and clinical trials
24, 36
. 
Undeniably, the understanding of immunosuppressive strategies mediated by 
tumor cells leads to development of more promising anti-cancer treatments. 
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1.2 Cancer immunotherapy 
Cancer immunotherapy aims to strengthen the cancer patient’s immune 
system
37
. Initial studies on cancer immunotherapy dated back to the late 1800s 
when Dr. William Coley concocted a mixture of killed Streptococcus pyogens 
and Serratia marcescens. The administration of Coley’s toxins was shown to 
eliminate carcinomas
11
. Currently, various clinical trials employing 
immunotherapy approaches are being conducted. A search on clinicaltrials.gov 
using the search terms “cancer immunotherapy” revealed 903 search results 
encompassing a wide range of cancer diseases (as of July 2013). Some of the 
major approaches in immunotherapy will be discussed below. 
1.2.1 Stem cells as cellular delivery vehicle for cancer gene 
immunotherapy 
1.2.1.1 Stem cell candidates for immunotherapy 
Stem cells are a population of cells that demonstrate self-renewal capacity and 
differentiation capability. With recent advances in the study of stem cells, 
different types of stem cells/progenitors such as mesenchymal stem cells 
(MSCs), neural stem cells (NSCs), hematopoietic stem cells (HSCs) or 
endothelial progenitor cells (EPCs) are believed to be ideal candidates as 
vehicles for anti-cancer gene delivery. Tumor microenvironments are 
abundant with various chemotactic cytokines and inflammatory signals that 
attract these progenitor cells. The migration of the cells toward tumor sites is 
mediated by chemokine receptors such as CXCR4 or CXCL12 on the stem 
cells
38
. Due to their tumoritropic properties, the principal advantage of stem 
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cell-based delivery of anticancer therapeutics is in its potential to achieve 
tumor-specificity, thus enhancing therapeutic effectiveness.  
Mesenchymal Stem Cells (MSCs) have been widely proven to be ideal 
vehicles for the targeted delivery of anticancer agents. This is attributed to 
their easy isolation from bone marrow or adipose tissues and enormous 
expansion potential in culture on top of their tumor-tropic capacities
38
. MSCs 
play an important role in maintaining tissue homeostasis by repairing injured 
tissues. A tumor microenvironment mimics that of a wound, thus attracting 
MSCs which can then be exploited to promote the growth of tumor stroma. 
Based on this, MSCs can be employed as cellular vehicles to send immune-
inducing agents to the tumor sites with the aim of killing the tumor cells via 
immune responses.      
Malignant brain tumors such as glioblastoma multiforme remain lethal 
and incurable
39
. Infiltrating immune cells are found in brain tumors, but their 
functions can be curbed by tumor-derived immunosuppressors as mentioned 
above. Recent studies have shown that intracranially or intravenously injected 
NSCs migrate toward brain tumors
40, 41
. Therefore, the NSCs-mediated 
immuno-stimulatory gene delivery system has the potential to significantly 
improve clinical outcomes for brain cancer patients.  
Another promising candidate for cellular delivery-based therapies is 
EPCs due to their involvement in tumor angiogenesis. In order to grow, 
tumors actively construct new vessels, and in the course of this 
neovascularization, circulating EPCs are actively incorporated into the tumor 
sites. Therefore, these cells can also be utilized as a ‘Trojan horse’ equipped 
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with immunostimulatory genes to kill the tumor cells. As Hamanishe et al. 
demonstrated, the systemic delivery of EPCs that express a lymphocyte 
migrating C-C chemokine ligand (CCL)-19 led to tumor repression in a 
murine ovarian cancer model. The use of EPCs is especially useful for 
targeting remote metastases as angiogenesis is a crucial factor in tumor 
metastatic progression.  
1.2.1.2 Stem cell delivery of cytokine for cancer immunotherapy 
Cytokines are biologic immune modulators produced by and acting on cells
11
. 
As mentioned above, cytokines play important roles in the regulation of 
immune responses and tolerance. Immunological manipulation using 
cytokines for cancer therapy has been prevalently attempted. For instance, IL2 
and IFNα have been used for the treatment of various cancers in the clinic 
such as renal cell carcinoma (RCC), AIDS related Kaposi’s sarcoma, 
melanoma, renal cancers and chronic myelogenous leukemia (CML)
11, 24, 42, 
43
.These cytokines act mainly by skewing the immune responses towards TH1 
axis, which in turn promotes CTL anti-tumor activities
11
. Although their 
efficacies have been proven under clinical conditions, the systemic 
administration of cytokines requires relatively high doses to obtain clinical 
effects. The non-specific and broad activation of the immune system by these 
cytokines can lead to life-threatening toxicities such as liver failure in human 
recipients
24
. The combination of the cytokine-mediated activation of immune 
responses and tumor suppression together with tumor-targeted delivery of 
transgene by stem cells is expected to provide therapeutic effects with minimal 
off-target toxic effects.   
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 MSCs have been widely used as a cellular vehicle to deliver immune-
stimulatory genes to tumors and tumor microenvironments to enhance 
antitumor immune responses. It has been shown that MSCs stably transduced 
with a retroviral vector expressing IL12 strongly reduced formation of lung 
metastases and retarded the growth of pre-established melanoma mouse 
model
44
. In another example, intra-tumor injection of primary mouse NSCs 
transduced with a retroviral vector encoding IL4 resulted in the extended 
survival of glioma-bearing mice
39, 45
. Likewise, intracranial injection of NSCs 
expressing IL12 into glioma mouse model resulted in the prolonged survival 
of the animals
46
. Moreover, human NSCs expressing IFNβ by adenoviral 
transduction reduced metastatic neuroblastoma upon injection
47
. These 
preclinical studies have spurred the idea of using stem cells as an excellent 
platform for tumor-specific cytokine-mediated cancer immunotherapies. 
1.2.1.3 Immunotherapy via in situ antibodies delivery by stem cells 
The current top-selling cancer drugs are monoclonal antibodies (mAbs) such 
as trastuzumab, rituximab and bevacizumab
27
. The anticancer effects of mAbs 
are based on multiple immunologic mechanisms, including complement-
mediated cytotoxicity, antibody dependent cytotoxicity and enhancement of 
adaptive immune response
27
. Trastuzumab (also known as Herceptin), is a 
human epidermal growth factor receptor 2- (HER2-) targeted antibody which 




Despite the promise shown by antibody-based therapies, the size, half-
life and toxic effects of these antibodies pose problems in clinical 
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circumstances. The large molecular size and short half-life of antibodies limit 
their ability to efficiently penetrate large solid tumors or tumor in obscure 
places, e.g. brain tumors whereby the antibodies are inefficient in crossing the 
blood brain barrier to exert their therapeutic effects. Moreover, toxic side 
effects due to interactions with unintended targets need to be resolved. A 
delivery vehicle system using stem cells can be harnessed to overcome these 
problems. The inherent tumor tropism of stem cells could be useful to deliver 
therapeutic genes to solid tumors and across blood brain barrier. 
Studies have shown that NSCs could deliver the tumor-specific anti-
HER2 antibody (functionally equivalent to commercially available 
Trastuzumab) in vivo
49, 50
. The anti-HER2 immunoglobulin-secreting NSCs 
exhibit preferential tropism to tumor cells in vivo and are capable of delivering 
tumor-specific antibodies to human breast cancer xenografts in mice
50
.  
Although promising, there are several critical challenges that require 
attention before stem cell-based gene immunotherapy is applied for clinical 
use. The first challenge is the choice and source of stem cells used for 
different types of cancer. It has been shown that NSCs perform better than 
MSCs in delivering an oncolytic adenovirus in a rodent orthotopic glioma 
model. Thus, NSCs may be a better candidate to deliver immunotherapeutic 
gene for brain tumors treatment. Another challenge is that this approach has to 
be able to produce the therapeutic agents of effective concentration at the 
tumor site. In addition to this, finding balance between therapeutic effects and 
tumor promoting effects as well as fine-tuning the gene expression and safety 
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of genetic engineering in the stem cells are important for this approach to be 
fully optimized in the clinics.    
1.2.2 Dendritic cell-based vaccinations 
Vaccines are one application of immunology that has successfully eradicated 
diseases such as polio and smallpox. Vaccines work by inducing protective 
immunity against the disease. The same principle applies to cancer vaccines in 
which the vaccines aim to stimulate tumor-specific immune responses for 
prophylactic (preventive) and therapeutic purposes. Two types of prophylactic 
vaccines have been approved by FDA, the vaccine against hepatitis B virus to 
prevent liver cancer and the vaccine against human papillomavirus (HPV) to 
prevent cervical cancer (Gardasil® and Cervarix®)
34
. In contrast, the 
development of therapeutic vaccines is more challenging. Recently, Provenge, 
a DC-based cancer vaccine for prostate cancer treatment, has been approved 
by FDA, inciting more studies for the development of next-generation DC-
based cancer vaccines.  
1.2.2.1 Dendritic cells as an excellent candidate for developing therapeutic 
vaccines against cancer  
There are several different approaches in cancer vaccines, including viral-, 
peptide-, vector-, tumor cell- and DC-based, each offering unique advantages 
and disadvantages
11
. DC-based vaccines aside, all these approaches are based 
on the presumption that they can stimulate DCs and generate immune 
responses in vivo. Unfortunately, these vaccines are likely to have poor 
pharmacokinetic properties and may be cleared rapidly before being loaded 
onto the DCs due to their short half-lives
34
. Moreover, as mentioned above, 
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the DCs in cancer patients may be functionally defective and induced to 
become tolerogenic DCs. Dendritic-cell-activating adjuvants such as GM-CSF 
and IL2 cytokines have been used together with these vaccines to boost their 
therapeutic efficacies. This underscores the importance of dendritic cells in 
regulating immune responses. Therefore, dendritic cells themselves become 
the obvious target and adjuvant tool-base for cancer vaccination. 
The approach of DC-based vaccines involves the isolation of DCs from 
the patients, followed by loading of antigens ex vivo, activation and 
conditioning to induce DC maturation, and finally re-infusion of the DCs back 
into the patient. The closest approach to DC-based vaccine by definition is 
Provenge, the only therapeutic vaccine to have been approved by the FDA to 
date. This vaccine, which comprises a mixture of the patient’s own PBMCs 
(Peripheral Blood Mononuclear Cells), prostate antigen PAP (Prostatic Acid 
Phosphatase) and GM-CSF supplement (DC growth and differentiation 
factor), is used for prostate cancer treatment
34
.  
1.2.2.2 Loading dendritic cells with tumor-specific antigens 
The development of DC-based vaccines requires the introduction of antigens 
into the DCs which in turn will present them to T cells. The antigens used can 
be in various forms and there are several methods to load them to DCs. To 
date, studies have used antigens in the form of DNA, peptides/proteins, RNA 
(mRNA/total RNA), exosomes and whole tumor cells (alive/killed). These 
antigens can be loaded into the DCs via viral vector-mediated gene transfer, 
electroporation, transfection as well as co-culture/mixing. 
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The advantage of using DNA to load antigens to DCs is that the tumor 
antigens will be expressed by the DCs and presented via MHC I complex in a 
way that mimics endogenous protein presentation
51
. Some studies have shown 
its efficacy in mounting cytotoxic effect against tumors
52-54
. However, since 
usually viral vector-mediated loading is adopted, this method raises safety 
concerns regarding the use of the virus and its effect on the transduced DCs.  
Antigen loading using peptides has the advantage of being specific, 
hence reducing the unwanted toxicities from non-specific immune responses
6, 
51
. Yet, this specificity is a double-edged sword, as it also limits the target 
cells. Moreover, as mentioned previously, the application of peptide-based 
vaccine is MHC restricted. However, the efficacy of using peptide-pulsed DCs 
for cancer immunotherapies has been proven in several studies and even in 
clinics
55-57
.    
Targeting a broader spectrum of tumor antigens without the restriction 
of MHC typing is sometimes preferred although such approaches are usually 
limited by the minute quantity of cancer antigenic molecules present. The use 
of proteins, total RNA, exosomes and whole cell-based antigens can achieve 
this. However, greater technical demands are required to prepare antigens 
from proteins, RNA and exosomes especially in large-scale productions and it 
is costlier too. Despite this, their efficacies in preclinical and clinical studies 
have been proven
58, 59
. Loading DCs with whole tumor cell antigens can be 
achieved with tumor lysate prepared by repeated freeze-thaw cycles or 
apoptotic cells generated by irradiation. This approach is simple yet well-
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established in DC-based vaccine immunotherapies and its therapeutic effects 
have been reported by many studies
60-64
. 
More research needs to be done since even the success story of 
Provenge can only deliver a meager 4-month advantage in overall survival
27, 
34
. A better understanding of DCs generation and differentiation, of immune 
tolerance and of tumor antigen choices, formulation and incorporation into the 
DCs will allow us to design a better cancer vaccine. 
1.2.3 Other approaches   
1.2.3.1 Adoptive T cells for cancer therapy 
Growing cancers contain tumor infiltrating lymphocytes (TILs), indicating the 
presence of T cell immune response against cancer. It has been shown that the 
prognosis of hepatocellular carcinoma (HCC) cancer patients with marked 
TILs is better than that of patients without TILs. Unfortunately, TILs very 
often succumb to the immunosuppressive and tolerogenic tumor 
microenvironment. This is why the idea of providing improved anti-tumor 
reactive T cells via adoptive T cell therapy becomes very promising.  
The feasibility of adoptive immunity was discovered after a study in 
mice revealed that specific immunity to tumors could be transferred to normal 
mice using lymphocytes from the spleen or peritoneal cavity of immunized 
donors
43
. The donation of T cells can be allogeneic or autologous. Though it 
has been performed with marked therapeutic effects in clinical condition, 
allogeneic donation may lead to graft-vs-host disease (GVHD). Thus, 
isolation, expansion and reinfusion of autologous tumor reactive T cells into 
the patient are more preferred.  
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T cells can be isolated from peripheral blood, tumor effusions or from 
draining the lymph nodes of the patient/donor
21
. Once obtained, the T cells are 
stimulated and expanded in vitro via priming with DCs which present the 
tumor antigens or using CD28/CD3 antibodies
11, 21, 24
. Regardless of the 
methods to isolate and expand the T cells, the challenge is to maintain the 
survival and properties of the cells after being re-injected into the patient
11, 24
.  
1.2.3.2 Genetic engineering of T cells  
Genetic engineering to confer T cells with a stronger and more specific tumor-
killing power has also been adopted. This can be achieved through tumor 
antigen-specific TCR gene transfer or introduction of chimeric antigen 
receptor (CAR)
1
. TCR gene transfer has been used in clinical trial for 
melanoma using melanoma tumor antigen melanin A (MART-1)
1
. Adoptive T 
cell transfer with an HLA-A2 restricted T cell receptor (TCR) specific for NY-
ESO-1, a cancer-testis antigen expressed by human cancers and testis but no 
other normal adult tissues, resulted in tumor regression in 5 out of 11 patients 
with melanoma and 4 of 6 patients with synovial cell sarcoma
27
. One 
drawback of this therapeutic regime is its limitation due to the MHC-
restriction.  
CARs, single-chain constructs composed of an Ig variable domain 
fused to a TCR constant domain, were developed to overcome this
21
. When 
introduced into the T cells, they combine the antigen recognition properties of 
antibodies with T cell lytic functions. Thus, this method broadens the 
spectrum of tumor antigen recognition and is not MHC-restricted. The first 
generation of CAR consists of a single signaling domain, CD3ζ. Although the 
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resulted redirected T cells are functional, they fail to persist in the long term. 
In the second generation of CAR, the CD28 signaling domain was added to 
confer resistance to the T cells. The newer generations include more co-
stimulatory molecules such as 4-1BB (CD137) domains to enhance T cell 
survival and function even further
1
. Encouraging early clinical results have 
been obtained in patients with lymphoma
65
. However, the toxicities as well as 




1.2.4 Challenges in cancer immunotherapy 
Despite surmounting evidence and convincing data in preclinical studies, 
cancer immunotherapies in clinical trials have failed to deliver promising 
results. Clearly, some roadblocks need to be cleared in order to attain success 
in clinical applications. One such hindrance is the limitations of preclinical 
animal models. The existing models, be it the syngeneic or xenograft models, 
have provided us with tools to understand the mechanisms of cancer 
immunology and immunotherapy. Yet, they are still far from recapitulating the 
complex and progressive pathophysiological of cancer in patients
66
. 
Improvements in animal models will result in better prediction of therapeutic 
efficacies in humans. Naturally occurring cancers have been observed in 
companion animals (pet dogs and cats)
67-70
. Understanding the biology and 
treatment of cancer in these animals may bridge the gap between preclinical 
and clinical studies closer.  
Another major roadblock hampering the success of cancer 
immunotherapy is the lack of understanding of the overall immune status of 
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patients. Mechanisms that suppress the immune system provide a fundamental 
reason why immunotherapy fails to induce consistently robust immune 
responses in patients
71
. Prescreening of patients for immune status will help 
identifying patients who are more likely to respond to certain therapies. 
Eventually, this knowledge will be useful in designing cancer therapy that will 
work for certain groups of patients with the same immune parameters. 
Development of biomarkers and assays that can test arrays of markers 
efficiently would be very valuable. Recently, a new generation of flow 
cytometry based on mass spectrometry readout of heavy metal ion-labeled 
probes has been developed
72-75
. This technology allows testing of 40 




While the heterogeneity of cancer is considered a critical hurdle, 
appreciating this complexity and designing therapeutic combinations holds 
great potential in clinics. There is a substantial evidence to suggest that some 
combinations of chemo- or radiotherapy and vaccine treatment are 
synergistic
66, 76, 77
. Other emerging therapeutic strategies that can be used in 
combination with current available therapies are antibodies targeting the 
immune checkpoint blockade (e.g CTLA-4) or antibodies targeting PD-1, 
which will lead to depletion of Tregs population. However, more preclinical 








1.3 Purposes and motivations 
The idea that our own immune systems could recognize and kill cancer cells 
have been supported by a large amount of evidence. Studies on cancer 
immune responses and immune tolerance have led to the emergence of various 
potential cancer immunotherapeutic modalities. Yet, only a few could 
eventually develop into clinical applications despite all the effort, time and 
funding invested in myriad clinical research studies and trials.  
One critical hurdle is breaking the immune tolerance barriers created 
by the tumor microenvironment. To achieve this, we need to equip immune 
effectors with the appropriate signals which not only activate but also maintain 
the anti-tumor immune responses long enough to eradicate the tumor cells. 
Another crucial challenge is to fine-tune the balance between the specificity 
and the efficacy of the cancer therapy. We need to design treatments which 
can abrogate the tumor heterogeneous cell population while minimizing the 
off-target toxicities against the healthy normal cells. Treatments that can 
overcome these obstacles will be very valuable in the clinics.   
Targeted immuno-gene therapy using the stem cell delivery vehicle is 
an attractive approach to create such a treatment. The inherent tumor tropism 
of the stem cells combined with the immune-stimulating gene can become a 
powerful cancer treatment modality. Endothelial progenitor cells (EPCs) is 
particularly an excellent choice of cellular vehicle, not only due to their tumor 
tropism but also their involvement in cancer angiogenesis. However, deriving 
sufficient amount of EPCs for effective clinical translation is one of the critical 
challenges. In this study, we sought to explore whether human induced 
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pluripotent stem (iPS) cells could be used as a reliable and accessible cell 
source to generate uniform human EPCs with cancer gene therapy potential 
(Chapter 2).  
The presence of TILs indicates that immune cells also possess natural 
tumor homing capability. Moreover, DCs, the immune cells which bridge the 
innate and adaptive immune arms, are capable of stimulating adaptive immune 
responses by presenting tumor antigen to the T cells. Thus, we turn our focus 
utilizing and stimulating these cells to overcome the immune tolerance barriers 
created by the tumor microenvironment. 
Another immense obstacle in finding a cure for cancer is the presence 
of cancer stem cells (CSCs). Most of the available cancer treatments including 
chemotherapy and radiation therapy, while proven as effective in reducing the 
tumor burden, cannot eliminate the chance of tumor recurrence in patients. 
This is because these treatments failed to target the cancer stem cells (CSCs) 
population. The surviving CSCs, with their self-renewal and differentiation 
capability, are capable of reestablishing the tumor mass. Thus, we aim to 
develop a targeted DC-based immunotherapy approach against this 









CHAPTER II: ANTITUMOR EFFECTS OF CD40 LIGAND-
EXPRESSING ENDOTHELIAL PROGENITOR CELLS 
DERIVED FROM HUMAN IPS CELLS IN A METASTATIC 








2.1.1.1 Definition, Sources and characterization 







stem cells that can differentiate into endothelial cells (ECs), the cells that 
make up the lining of blood vessels
79-82
. EPCs are also identified by a set of 
markers, including the von Willebrand Factor (vWF), CD31 and vascular 
endothelial (VE)-cadherin
80, 83
. EPCs play significant roles in vasculogenesis 
(formation of blood vessels by in situ differentiation of EPCs), angiogenesis 
(development of pre-existing blood vessels) and the growth of solid tumors. 
Over the past decade, the observation that circulating EPCs from the bone 
marrow can be recruited into tumor neovessels has promoted many studies 
using various sources of endogenous and exogenous EPCs for therapeutic 
targeting to inhibit tumor neovasculaturization
81, 83, 84
. The systemic delivery 
of therapeutic gene-loaded EPCs can potentially enable efficient therapy for 
metastatic cancer by targeting multiple metastases in different sites through 
circulation, and this is probably the most attractive feature of EPC cellular 
vehicles in cancer treatment
85, 86
. 
In vitro, EPCs can be isolated from various sources, such as peripheral 
blood, bone marrow, adipose tissue and umbilical cord blood
87, 88
. However, 
the relatively low yield and difficult expansion of these cells pose a challenge 
for clinical usage. With the increasing potential to use EPCs as cancer 
therapeutics, it is desirable to have a reliable and stable supply of human 
EPCs. Pluripotent stem cells, such as embryonic stem (ES) cells, can be 
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expanded indefinitely in culture and have the potential to generate different 
types of cells, including endothelial lineage cells
87, 89-92
, in vitro in virtually 
unlimited numbers. Interestingly, mouse embryonic EPCs have been shown to 
be able to target lung metastases in an allogenetic setting in mice
83, 85, 93
. Most 





 endothelial cells armed with herpes simplex virus truncated 




Induced pluripotent stem (iPS) cells are another type of commonly 
used pluripotent stem cells. Human iPS cells appear more attractive for 
clinical applications since these cells can be generated relatively easily 
through reprogramming differentiated somatic cells with transcription factors, 
a procedure that circumvents the bioethical controversies associated with the 
derivation of human ES cells from human embryos
95-98
. Utilizing iPS cells to 
generate EPCs therefore holds great potential for clinical applications. 
2.1.1.2 EPCs gene therapy strategies  
2.1.1.2.1 Suicide gene therapy 
The major challenges of cancer therapy using cytotoxic drugs are the short 
drug half-life, insufficient delivery of the drug to tumor and their suboptimal 
specificity to malignant tissue. Tumor-targeted suicide gene delivery by stem 
cells will alleviate these issues. This therapy involves the stem cell-delivery of 
an enzyme which converts an inactive non-toxic pro-drug into a cytotoxic 
agent. Subsequently, the toxic drugs kill the cancer cells via bystander effects 
through diffusion or formation of gap junctions.  
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The first study to show that embryonic EPCs can be used as cellular 
vehicles to systemically deliver a suicide gene for cancer therapy was done by 
Wei et al
99
. In this study, cytosine deaminase/5-fluorocytosine (CD/5-FC) was 
used to treat mice with metastatic lung cancer. This CD/5-FC enzyme/prodrug 
system utilizes the conversion of an inactive non-toxic prodrug into a 
cytotoxic drug metabolite through the enzyme, cytosine deaminase. The 5-FC 
prodrug, an antifungal agent, will be converted to a diffusible and highly 
cytotoxic DNA synthesis inhibitor compound, 5-fluorouracil (5-FU), upon 
injection. Another suicide gene which has been extensively studied is the 
herpes simplex virus thymidine kinase/ganciclovir (HSVtk/GCV) system. In 
this system, HSVtk mediates GCV conversion to GCV 5’-triphosphate, which 
inhibits cell DNA polymerase
100
. HSVtk delivered by EPCs has been used to 
treat mice models of human ovarian cancer
83
.  
Although suicide gene therapy has been widely used and studied, it has 
limitations too. The bystander killing effect of the suicide gene requires time. 
Hence, it may not be able to compete with fast progressing tumor cells, or 
tumor cells in large amounts. Furthermore, the suicide gene vehicle has an 
inherent disadvantage, since it destroys itself, thus limiting the therapeutic 
window time
99
.    
2.1.1.2.2 Antiangiogenic therapy 
The growth and progression of solid tumors are dependent on newly formed 
blood vessels for cancer cells to get nutrients, as well as for a route via which 
the tumor cells can form metastases
79, 101
. Antiangiogenic therapy follows a 





prolonged administration of high doses of angiogenic inhibitors such as 
endostatin, thrombospondin or angiostatin in vivo is commonly required to 
produce antitumor effects due to its short half-life in circulation
83, 101
. Thus, 
EPC cellular delivery-based antiangiogenic gene therapy, which facilitates 





Several studies have demonstrated the use of EPCs to deliver immuno-
therapeutic genes for cancer therapy. One such studiy was done by Ojeifo et 
al., in which the administration of 3 sequential i.v (intravenous) injections of 
10
5
 ECs expressing the human IL2 transgene abrogated the tumor metastases 
and prolonged the survival of C57Bl/6 mice harboring lung metastases from 
melanoma
83, 103
. In another study, using mouse embryonic EPCs (eEPCs) 
which were retrovirally transduced with the mouse CC chemokine ligand-19 
(CCL19) gene, Hamanishi et al. showed the suppression of growth and 
metastasis of murine ovarian cancer in animal models. CCL19 elicits 
chemotactic activity for T cells, B cells and mature DCs, which supports the 
homing of naïve T cells and DCs into T cell areas of secondary organs. The 
tumor repression was accompanied by increased numbers of tumor infiltrating 
CD8
+
 lymphocytes. In contrast, no tumor repression was observed when the 
same experiment was done in immunodeficient (SCID) mice, suggesting that 
the crucial role of T cell function in this system
104
.  
The use of immune modulators for cancer therapy has been discussed 
in the previous chapter. However, the systemic administration of such immune 
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modulators can evoke toxic effects to the body due to their broad range of 
immune effects. Delivering their genes to the tumor sites via stem cells may 
lead to a more targeted approach to killing tumor cells, thereby attenuating the 
toxic effects.  
2.1.2 CD40 ligand  
CD40 ligand (CD40L) is a 33kDA type II membrane protein, a member of the 
TNF gene family. These ligands interact with CD40 receptors, which are 
expressed by a wide range of cells including antigen presenting cells (APCs), 
B cells, epithelial cells, endothelial cells (ECs) and malignant cells
105
. Since it 
was shown to have an antitumor effect in 1997 by Grossmann et al., many 
have studied the potential of CD40L as a cancer therapeutic agent. Binding of 
CD40L with CD40 receptors on APCs, such as dendritic cells, will result in 
the maturation of APCs. This, in turn, activates antitumoral T cell responses 
against cancer cells
106, 107
. Interestingly, studies using CD40L in 
immunodeficient mice showed delayed tumor progression, which may indicate 
other mechanisms than the T cell responses. In B cells, cross-linking CD40 
drives differentiation, proliferation and immunoglobulin class switching while 
preventing B cell apoptosis
107
. Meanwhile, Gomez et al. showed that tumor 
cells treated with AdCD40L had decreased viability due to apoptosis induction 
by CD40L
106, 108
. Currently, there are several ongoing clinical investigations 
utilizing adenoviral-CD40L, involving diseases such as CLL (chronic 
lymphocytic leukemia), acute leukemia, urinary bladder cancer and malignant 
melanoma 
106
. Moreover, humanized anti-CD40 monoclonal antibody SGN-40 





2.1.3 Induced pluripotent stem cells 
The iPS cells have provided us with a tool to generate EPCs perpetually. 
However this groundbreaking technology would not come about if not 
supported by abundant prior studies and knowledge on stem cells. One such 
impactful study is the work on somatic cells nuclear transfer (SCNT)
109
. This 
technique allow the generation of fully-functioned organisms, although 
usually with severe genetic abnormalities, from differentiated cells as nuclear 
donor and cytoplasm of an oocyte. Studies have also shown that various cell 
types have the capacity to functionally influence or reprogram one another 
following cell fusion
110
. Interestingly, pluripotent cells (ESCs or embryonic 
carcinoma cells) have the superiority to reprogram the differentiated cells
111, 
112
. Both methods take advantage of cellular materials, either the nuclear 
factors present in the cytoplasm of the enucleated oocyte or in the hESCs 
fused to the adult cells, to establish pluripotency in somatic cells
113, 114
. 
Yamanaka and colleagues ingeniously compiled 24 ‘candidate factors’: 
genes that were known to be highly associated with pluripotency. After 
removing the factors one by one, the final Yamanaka reprogramming factors, 
Oct4, Sox2, Klf4, and C-Myc, were deduced to be crucial to reprogram adult 
cells back into pluripotent state
110
. These genes encode for transcription 
factors which activate the expression of genes in the pluripotency network and 
suppress those that promote differentiation via chromatin remodeling
114
. Oct4 
has been shown to be indispensable factor in the reprogramming cocktails. It 
forms heterodimers with Sox2 to attain a more stable and efficient DNA 
binding
115, 116
. Klf4 or Kruppel like factor 4 is a zinc finger transcription factor 
that regulates cell proliferation and differentiation
116
. Although dispensable, 
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C-Myc has been known to induce changes in histone methylation patterns, 
thus providing easier access to the reprogramming factors and enhancing the 
efficiency of the reprogramming process
116
.  
Although iPS cells hold great promise in cancer and regenerative 
medicine, it has to pass critical safety concerns prior entering the clinics. One 
concern is the use of viral systems that result in integration of the 
reprogramming factors into the host cell genome and subsequently may lead to 
mutagenesis and tumorigenesis
117
. Non-integrating approaches using vectors 
that do not integrate into host cell genome or that could subsequently be 
removed from the genome are preferred
112
. Another concern is the oncogenic 
nature of all the reprogramming factors. Thus, transient expression of these 
factors is favored
117
. One potential clinical application of iPS cells is the 
establishment of HLA-matched banks of lines. The use of hESCs for this 
purpose hits a major ethical block as it requires embryos to derive the cell 
lines. Furthermore, limited availability of hESCs derived from surplus 
embryos donated following IVF treatment is unlikely to provide sufficient 
numbers to populate a highly selected cell bank
118
. Collection of adult cells 
that can be used to derive iPS cells banks would be more feasible and less 
controversial. 
2.1.4 Objective and Aim of Study 
The overall aim of our study is to investigate the anti-tumor effect of CD40L 
while utilizing EPCs as the cellular delivery vehicle. Most studies utilized 
CD40L expression in DC or tumor cells in order to activate T cell 
responses
105, 106, 108, 119, 120
. However, in this study, we used EPC as a cellular 
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vehicle to deliver the CD40L systemically and tested its therapeutic effect on 
4T1 metastatic breast cancer model in mice. It has been shown that CD40L 
can bind to the receptors located on ECs, which results in the localization of 
leukocytes to the tumor endothelium via cytokines and chemokines 
production
121
, thus justifying our selection of EPCs as cellular vehicles for 
CD40L as cancer therapy. 
The criteria for an excellent cellular delivery vehicle include simple 
production and expansion, capability for tumor tropism, feasibility of gene 
transfer, and ability to exert therapeutic effects. We will investigate whether 
our produced EPCs possess these traits in this project. In the first part of the 
study, we investigated the derivation and characterization of EPCs from 
hPSCs, both the hESCs and the iPS cells.  
We continued by observing the tumor tropisms of EPCs toward cancer 
cells. We employed a dual-color imaging system, making use of luminescent-
based luciferase and fluorescent-based near-infrared DiR systems. Using this 
method, we tracked both the growth of tumor cells expressing luciferase and 
the distribution of DiR-labeled cells after injection into the mice non-
invasively over time. The tumor tropisms of EPCs in different mouse tumor 
models were investigated: the 4T1-luc mammary pad model, 4T1-luc lung 
metastatic model and orthotopic glioma model.  
Though attractive, the tumor tropic properties can be a double edged 
sword. Mesenchymal stem cells (MSCs) are also favored as cellular vehicles 
due to their tumor tropism. Yet, it has been noted that MSCs may contribute to 
tumor growth by promoting angiogenesis, modulating the immune response 
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against cancer cells and promoting metastasis
122-124
. Hence, the therapeutic 
effects exerted by the transgene expressed via these cellular vehicles must be 
able to overcome the ability of these cells to sustain cancer cells. We 
investigated the capability of iPS-EPCs in tumor growth and 
immunomodulation alongside iPS-NSCs, another well-known cellular vehicle. 
We went on to test the feasibility of gene transfer in hPSCs-derived 
EPCs. We focused on the use of baculovirus to facilitate the gene transfer to 
EPCs. Baculoviral vectors, which are derived from an insect virus Autographa 
californica multiple nucleopolyhedrovirus, emerged as a potentially safe class 




Finally, we investigated the cancer immunotherapeutic efficacy of 
CD40L delivered by EPCs in a mouse tumor model. We also examined the 
therapeutic effects of the HSVtk gene, the golden standard of the suicide gene 
therapy. Recently, a novel angiogenesis inhibitor, Isthmin (ISM), has been 
reported. Originally identified in Xenopus brains, this 60kDa protein could 
suppress mouse melanoma tumor growth when overexpressed
126, 127
. Whether 
ISM could inhibit tumor growth in pre-established tumors in mice when 
delivered systemically, will be investigated in this study. 
2.2 Material and Methods 
2.2.1 Cell culture 
H1 or H9 hESC lines (WiCell, WI, Madison, USA) were cultured in 
mTeSR
TM
1 medium (Stemcell Technologies Inc, Vancouver, Canada) on 
hESC-qualified matrigel (BD Biosciences, San Jose, California, USA). Human 
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iPS cells were generated by utilizing a Cre-excisable polycistronic lentiviral 
vector containing Oct4, Klf4, Sox2 and c-Myc genes (Millipore, Bedford, 
MA) as stated in our previous study
128
. The generated iPS cells were also 
cultured on hESC-qualified matrigel using mTeSR
TM
1 medium. For 
passaging, confluent H1 or iPS cells were washed twice with 1× Dulbecco’s 
phosphate-buffered saline (DPBS) without calcium and magnesium (Gibco, 
Invitrogen, Carlsbad, CA). Then 1 ml dipase (1 mg/ml; Gibco, Invitrogen) was 
added to dissociate the cells in a 37
o
C incubator for 5 min. The cell colonies 
were gently scraped off with a 20 µl pipette tip and seeded onto a new 
matrigel-coated 6-well-plate (Nunc, Penfield, New York, USA). A medium 
change was performed every day until the next passaging at day 7. 
Mouse 4T1-luc is a breast cancer cell line that stably expresses the 
luciferase gene (Caliper Life Sciences, Hopkinton, MA, USA). These cells 
were passaged every 4 days at a split ratio of 1:5 and maintained in a RPMI-
1640 medium (Gibco, Invitrogen) supplemented with 10% FBS (fetal bovine 
serum, Hyclone, Waltham, Massachusetts, USA) and 1% 
penicillin/streptomycin (P/S; Gibco, Invitrogen). M2-10B4 mouse bone 
marrow stroma cells (ATCC, Manassas, Virginia, USA) were also maintained 
in this medium, but passaged in 1:10 ratio every 4 days. OP9 cells (ATCC) 
were maintained in α-MEM (Gibco, Invitrogen) supplemented with 20% FBS. 
OP9 cells were passaged every 4 days at a split ratio of 1:8. T-75 cm
2
 flasks 
(Nunc) were coated overnight with 6 ml of 0.1% gelatin A (Sigma-Aldrich, St. 
Louis, Missouri, USA) prior to OP9 cell seeding. HUVEC (Lonza, Basel, 




To subculture the cells, the confluent cells were washed twice with 1× 
DPBS and treated with 1× trypsin-EDTA (Gibco, Invitrogen) for 5 min in an 
37
o
C incubator. The trypsinized cells were then collected and rinsed with the 
cell culture medium to neutralize the trypsin. The cells were centrifuged at 
200-300g for 5 min. Then, the cells were re-suspended in the cell culture 
medium and seeded onto a new flask according to the appropriate split ratio. 
All the cells were maintained in a 5% CO2 humidified incubator at 37
o
C. 
2.2.2 Stromal-based EPC derivation method 
2.2.2.1 OP9 co-culture 
To prepare for hematopoietic differentiation of hPSCs, OP9 cells were 
cultured in T-175 cm
2
 flasks (instead of T-75 cm
2
) for normal culture 
maintenance. When they became confluent on day 4, half of the medium was 
changed, and the culture dishes were maintained for an additional 4 days. On 
day 8, the super-confluent OP9 medium was replaced with 20 ml of 
hematopoietic differentiation medium, the α-MEM supplemented with 10% 
FBS and 100 μM monothioglycerol (MTG; Sigma Aldrich). Three wells of a 
6-well-plate of confluent hPSCs were harvested and added to each dish of 
overgrown OP9 cells. The flask was tapped and swirled gently to ensure that 
the hPSCs colonies were well distributed throughout the co-culture before 
putting it into the 37
o
C incubator. The differentiation medium was fully 
replaced at day 1, and from day 4 of the co-culture, half of the medium was 
changed every 2 days.  
The cell co-cultures were harvested at day 8 using collagenase IV 
treatment for 10 min, followed by trypsin for 10 min. The cell suspension was 
36 
 
then filtered through a 70 μM nylon cell strainer (BD Labware, Bedford, MA, 
USA). The harvested cells were then magnetically sorted using CD34 
microbeads (Miltenyi Biotec, Cologne, Germany). The sorted EPCs were 
seeded on fibronectin-coated plates in EGM-2 medium. Fibronectin was used 
as the extracellular matrix as it has been shown to improve endothelial cell 
adhesion and seeding efficiency
129
.  
2.2.2.2 M2-10B4 co-culture 
To prepare M2-10B4 as stromal cells, the confluent cells were treated with 
mitomycin C (10ug/ml; Roche, Basel, Switzerland) for not more than 3 h. The 
cells were then collected, seeded onto a T-175 cm
2
 flask (4.5e6 cells/flask) and 
were allowed to settle overnight in a 37
o
C incubator with 5% CO2. The next 
day, the hPSC colonies were seeded onto the M2-10B4 stroma as explained 
above. The co-culture medium used was RPMI-1640 supplemented with 15% 
FBS, 1 mM NEAA (Non-Essential Amino Acids; Invitrogen) and 0.1 mM β-
mercaptoethanol (Gibco, Invitrogen). The medium change was performed 
every 2-3 days. The co-cultures were harvested after 13 days using the same 
method as above. 
2.2.3 Non-stromal-based EPC derivation method 
2.2.3.1 2-D culture 
For 2-D monolayer differentiation, the method was drawn from a published 
article
130
, with some modifications. Undifferentiated hPSCs were cultured at a 
higher density on matrigel for 7 days. At the start of the differentiation phase, 
the culture medium was changed to a 2-D differentiation medium, IMDM 
supplemented with 15% defined-FBS (Hyclone), 450 µM MTG, 2 mM L-
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glutamine (Gibco, Invitrogen), 1× P/S and 0.1 mM NEAA. The medium was 
changed every 2-3 days for 10 days. After differentiation, the single-cell 
suspensions were prepared by treatment with 2 mg/ml collagenase B (Roche) 




 cells were then isolated as mentioned above. 
2.2.3.2 Embryoid bodies method 
The confluent hPSC cultures were treated with 1 mg/ml dispase for 5 min. 
After dispase was removed, the cells were washed twice with PBS. The 
colonies were then detached by scraping the colonies with a pipette tip. The 





 medium (Stemcell Technologies Inc) to form embryoid bodies (EBs) 
for 4 days. This animal product-free medium has been shown to result in 
superior reproducibility of EB formation and high efficiency of 
differentiation
131
. Afterwards, the formed EBs were plated onto a matrigel 
coated 10-cm culture dish and cultured for another 10 days.  Cytokines 
(Peprotech, Rocky Hill, New Jersey, USA) were added to supplement the 
medium as follows: 20 ng/ml BMP4 (day 0-7), 10 ng/ml Activin A (day 1-4), 
8 ng/ml FGF2 (day 2 onwards), and 25 ng/ml VEGF (day 4 onwards). In 
addition, a TGF-β inhibitor, 10 μM SB431542 (Tocris Bioscience, Bristol, 
UK) was added from day 7 onwards
132
. On day 14, the cells were harvested by 
treatment with collagenase IV (Gibco, Invitrogen) for 10 min, followed by 
trypsinisation (trypLE, Invitrogen) for another 10 min. The harvested cells 
were then magnetically sorted using CD34 microbeads. The sorted EPCs were 
seeded on fibronectin plates in Endothelial Growth Medium-2 (EGM-2 
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medium, Lonza) supplemented with 10 μM SB431542. The cells from 
passages 2 and 3 were used for characterization and animal experiments. 
2.2.4 Characterization of EPCs 
2.2.4.1 Flow cytometry 
Generated iPS-EPCs were characterized by flow cytometric analysis using 
anti-CD34, CD31, Flk1, CD144, CD45 antibodies (BD Biosciences) and anti-
CD133/1 antibody (Miltenyi Biotec). Quantitative analyses were performed 
using FACSCalibur flow cytometer (BD Biosciences).  
2.2.4.2 Immunostaining 
Immunofluorescent staining was prepared using primary anti-von Willebrand 
factor (vWF; Abcam, Cambridge, UK) and secondary fluorescent Alexa488 
conjugated anti-rabbit antibodies (Invitrogen). Antibodies were diluted at 
1:200 in 1% BSA/PBS. Hoechst (Invitrogen) was used to stain the nucleus of 
cells. Immunofluorescence was visualized and images were captured using an 
Olympus image analysis system (Olympus, Tokyo, Japan). 
2.2.4.3 Tubulogenesis assay 
For tubulogenesis assay, a 48-well-plate was coated with matrigel (150 
µl/well) and incubated at 37
o
C for 1 h. EPCs were then seeded on the matrigel 
coated plates, 2×10
4
 cells/well, in 250 µl EGM-2 medium and incubated at 
37
o
C overnight. The tube-like structures were photographed under a phase-




2.2.4.4 DiI-Ac-LDL assay 
To test the ability of our iPS-EPCs to uptake acetylated-LDL (Ac-LDL), the 
cells were incubated with 1,1’-dioctadecyl 3,3,3’,3’-tetramethylindo 
carbocyanine perchlorate (DiI-Ac-LDL; Invitrogen) at a concentration of 10 
µg/ml in EGM-2 for 4 h at 37
o
C. After washing, the cells uptaking Ac-LDL 
were observed by their fluorescent signal under the microscope and 
photographed.  
2.2.5 Baculoviral vector preparation 
Recombinant baculoviral vectors expressing eGFP, mouse Isthmin, HSVtk or 
CD40L were constructed using the BAC-to-BAC baculovirus expression 
system according to the manufacturer’s manual (Invitrogen). These genes 
were under the control of a CMV promoter with the R segment and part of the 
U5 sequence of long terminal repeat from the human T-cell leukemia virus 
type 1 at 5’ UTR and the woodchuck hepatitis virus posttranscriptional 
regulatory element (WPRE) at 3’ UTR. The constructs were produced by 
homologous recombination after co-transfection of Sf9 insect cells with 
pBacPAK9 transfer vector containing the expression cassette and linearized 
AcMNPV viral DNA (Clonetech, Mountain View, CA, USA).  The 
recombinant baculoviruses were propagated in Sf9 insect cells (Invitrogen) at 
an MOI of 0.1 in Sf-900 II SFM (Invitrogen) and maintained at 27
o
C. The 
virus-containing supernatant was collected 3 days after virus infection. The 
budded viruses in the insect cell-culture medium were centrifuged at 1000 g 
for 10min to remove cell debris, and concentrated by a second round of 
centrifugation at 28,000 g for 1 h.  
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Virus pellets were re-suspended in 1× PBS and virus titers were 
determined by real time PCR for Gp64 expression. Viral DNA was isolated 
using a Viral DNA purification kit (Roche). For real time PCR, the forward 
and reverse primers used were gp64-F1337-S23: 5'- 
AAAGCAACCTCATAACCACCATG, and gp64-R1429-A20: 5'- 
CCAATTCGCCTTCAGCCATG. The Taqman probe gp64-P1395-A21 was 
labeled with FAM (6-carboxy-fluorescein) at the 5’-end and a non-fluorescent 
dark quencher, BHQ1(Black Hole Quencher), at the 3’-end, 6-FAM-5'-
CAGACTGGTGCCGACGCCGCC-BHQ1. The PCR sample mix was as 
followed: 100 nM primers and Taqman probes, 2X iQ Supermix (Bio-Rad, 
Hercules, California, USA), 2 μl template viral DNA or water as the non-
template control to a final volume of 25 μL. The thermal cycling included an 
initial denaturation step of 3 min at 95°C, followed by 40 cycles of 95°C for 
15 sec, and 60°C for 1 min with fluorescence detection. For all real-time 
amplifications, triplicates of five 10-fold dilutions of the plasmid DNA 
standards, viral DNA samples and non-template water controls were 
simultaneously subjected to analysis. 
For baculoviral transduction, cells were transduced in at a multiplicity 
of infection (MOI) of 100 plaque forming units (pfu) per cell overnight. A full 
change of medium was done the next day to remove the viral particles and 
stop the transduction. GFP expression was detected under a fluorescence 
microscope and by flow cytometric analysis. To confirm CD40L gene 




2.2.6 Animal studies 
2.2.6.1 Animals 
Pathogen-free, 6 to 8 week-old immunocompetent BALB/c mice, 





/SzJ mice from Jackson Laboratory, USA) were 
used in this study. All handling and care of animals were carried out according 
to the Guidelines on the Care and Use of Animals for Scientific Purposes 
issued by the National Advisory Committee for Laboratory Animal Research, 
Singapore. 
2.2.6.2 Dual in vivo imaging system  
Mouse 4T1-luc was utilized to facilitate in vivo bioluminescent imaging. To 
generate an orthotopic breast cancer model, the cells were injected 
subcutaneously onto the mammary fat pad (1×10
5
 cells in 50 µl PBS). To 
generate a breast cancer lung metastasis model, 4T1-luc cells were injected 
intravenously via the tail vein of the mice (1×10
4
 cells in 200 µl PBS). To 
monitor the bioluminescent signals of 4T1-luc in the mice, isoflurane gas-
anesthetized animals were injected intraperitoneally with D-luciferin 
(Promega, Madison, Wisconsin, USA) at 100 mg/kg in PBS. 
To observe the biodistribution of iPS-EPCs in the mice non-invasively 
over time, a lipophilic, near-infrared fluorescent dye 1,1'-dioctadecyl-3,3,3',3'-
tetramethyl indotricarbocyanine iodide (DiR; Caliper Life Sciences) was used 
to label the cells. Cells were labelled with 50 µg/ml DiR for 30 min in a 37
o
C 
incubator. After labelling, the cells were washed three times with 1× PBS. 





 in 200µl PBS) or via an intratumor injection (5×10
5
 in 100µl 
PBS).  
After injections, whole animal imagings were performed at day 1, 3, 7 
and 14 to track the migration of the iPS-EPCs and observe the tumor growth. 
Briefly, the mice were placed on a warmed stage inside the camera box of the 
IVIS imaging system coupled with cool CCD camera (Xenogen, Alameda, 
CA, USA). Images and measurements of luminescent signals were acquired 
and analyzed with the Xenogen living imaging software v2.5 and quantified as 
photons per second. 
2.2.6.3 Biodistribution of EPCs in intracranial 2M1 tumor model 
Invasive human glioma cell line 2M1 previously established in our lab was 
used to test the biodistribution of EPCs in the mouse glioma model
133, 134
. To 
investigate iPS-EPCs distribution in the tumor, 5×10
5
 2M1 cells were labeled 
with green fluorescent dye CM-DiO (Invitrogen) and inoculated into the right 
side of the nude mouse striatum. One week later, 1×10
6
 iPS-EPCs, which were 
labeled with CM-DiI dye (Invitrogen), were injected at the same site of the 
tumor injection. Brain tissues were collected one week after the EPCs 
injection for sectioning and examination. 
2.2.6.4 Therapeutic studies of EPCs 
To investigate therapeutic effects of iPS-EPC-mediated gene delivery, the 
breast cancer lung metastasis model in nude (nu/nu) BALB/c mice described 
above was used. At day 3 post-tail vein injection, mice were randomly divided 
into different groups (n = 10 per group). For the CD40L experiment, the 
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groupings were as follows: PBS, iPS-EPC, iPS-EPC-Bacpak and iPS-EPC-
CD40L. For the HSVtk experiment, the groupings were: PBS, iPS-EPC, iPS-
EPC-HSVtk and iPS-EPC-HSVtk+GCV. Lastly, for the isthmin experiment, 
the groupings were: PBS, iPS-EPC, iPS-EPC-Bacpak and iPS-EPC-misthmin.  
The iPS-EPCs were transduced with the respective recombinant 
baculovirus at an MOI of 100 pfu per cell. Three days after tumor inoculation, 
baculovirus-transduced iPS-EPCs (1×10
6
 in 200 μl PBS per animal) were 
injected into the mice through the tail vein. Tumor growth was monitored 
using whole-animal imaging as described above and animal survival rates 
were recorded. 
2.2.7 Histology 
The collected organs from mice were submerged in 4% paraformaldehyde for 
24 h. The organs were then transferred into a 30% sucrose solution and were 
immersed in 30% sucrose for another 24 h. Subsequently, the tissues were 
embedded in Jung tissue freezing medium (Leica Microsystems, Gmbh, 
Nussloch, Germany). Organs were then frozen and placed in a -80
o
C freezer 
for storage. Sections 12μm thick were taken with a Leica CM3050S cryostat 
(Leica Microsystems, Wetzlar, Germany). They were then observed with a 
confocal microscope. 
2.2.8 Statistical analyses 
All data are represented as mean ±SD. The statistical significance of 
differences was determined by one-way ANOVA. The statistical analysis of 
survival data was performed using the Gehan-Breslow log rank test followed 
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by the Holm-Sidak method for pairwise multiple comparison tests. A p value 
of <0.05 was considered to be statistically significant. 
2.3 Results 
2.3.1 Generation of EPCs from Human Pluripotent Stem Cells 
2.3.1.1 OP9 co-culture method 
We first derived EPCs from hESC line H1 via co-culture with OP9 mouse 
stromal cells according to a previously published protocol by Vodyanik and 
Slukvin (Fig. 2.1A)
135
. The super-confluent OP9 cells ready for co-culture is 
shown in Figure 2.1B, whereas Figure 2.1C shows an example of a healthy 
undifferentiated H1 colony.  The H1 colony was nicely seeded and attached on 
top of the OP9 stroma forming a button-like structure (Fig. 2.1D left). On day 
4 of the co-culture (Fig. 2.1D middle), the H1 cells differentiated by forming 
organized root-like structures that penetrated the OP9 portion of the co-culture 
and spread away from the button-like structure.  The root-like structures grew 
thicker over time, as seen in the image of the co-culture on day 6 (Fig. 2.1D 
right). After 8 days of co-culture, the cells were harvested and the CD34
+
 cells 
were then sorted by two rounds of selection using the Magnetic Assorted Cell 
Sorting (MACS) method. From one T-175 cm
2
 flask, in which three wells of a 







cells after two rounds of MACS. The cells showed typical cobblestone EPC 
morphology, after they were reseeded on a fibronectin-coated plate (Fig. 
2.1E).     
We observed the percentage of CD34
+
 cells by using flow cytometry 
(Fig. 2.1F). Before sorting, the percentage of CD34
+
 cells varied from 5-10%. 
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After two rounds of sorting via MACS, the purity of the CD34
+
 cells can reach 
up to 80-99%. Most of the sorted CD34
+
 cells also co-expressed the CD31 
marker (82.84%) as well as Flk1 (75.92%). On the contrary, the CD45 marker 
was expressed at a very low level (3.28%). Furthermore, these cells can 
maintain the CD34 and CD31 markers for up to four passages (Fig. 2.1G). 
The sorted EPCs formed tube-like formations upon seeding on matrigel (Fig. 
2.1H), another in vitro characteristic of EPCs.  
EPCs can also be generated from iPS cells (Fig. 2.2A) via the OP9 co-
culture method. The co-culture of iPS colonies and OP9 cells at day 8 also 
displayed outward root-like expansion, similar to that of H1-OP9 co-culture 
(Fig. 2.2B). The resulting EPCs after sorting had similar morphology (Fig. 
2.2C) and expression of endothelial markers shown by flow cytometry (Fig. 
2.2D) as that of H1-EPCs. Furthermore, these cells also had the capability of 





Figure 2.1. Derivation of hESC-derived EPCs via mouse stromal OP9 co-culture. A. 
Schematic diagram on the OP9 co-culture protocol. H1 colonies were co-cultured with 
overgrown OP9 culture for 8 days. CD34
+
 cells were then collected using magnetic cell 
sorting. B. Super-confluent OP9 at day 8 ready for co-culture. C. H1, hESC cell line 
colony. D. Co-culture of H1 and OP9 at different time points (Left to right: day 1, 4 and 
6). E. EPCs at day 5 after CD34
+
 magnetic sorting on fibronectin-coated dish. F. 






 before and after sorting 
process via flow cytometry. EPCs expressed very low CD45 markers, hematopoietic 
lineage markers. G. Expression of CD34 and CD31 after 2nd passage of EPCs. Most of 
the cells still co-expressed these markers (95.93%). H. EPCs form tubule-like formation 




Figure 2.2. iPS-derived EPCs produced via mouse stromal OP9 co-culture. A. 
Colonies of iPS cells. B. iPS co-cultured on OP9 stromal cells after 8 days. C. iPS-
EPCs after sorting by MACS seeded onto fibronectin coated dish. D. Flow cytometry 
showing the percentage of CD34 and CD31 markers in the cells before and after 
sorting via MACS. E. iPS – EPCs form tubule-like formation when seeded onto a 
matrigel-coated dish. 
 
2.3.1.2 M2-10B4 co-culture method 
M2-10B4 is a mouse bone marrow stroma cell that can support 
hematoendothelial differentiation
136, 137
. Thus, we also used this cell line 
alongside OP9 cells to generate EPCs from hPSCs (Fig. 2.3A). After reaching 
confluency (Fig. 2.3B), M2-10B4 cells will be treated with mitomycin C in 
order to prepare mitotically inactive feeder cells for the co-culture. The cells 
were then washed extensively with PBS before being reseeded onto a T-175 
cm
2
 flask and allowed to settle in a 37
o
C incubator overnight. The next day, 
colonies of H1 or iPS cells were seeded onto the M2-10B4 feeder cells (Fig. 
2.3C). The M2-10B4 co-culture process took a longer time of 13 days, 
compared to OP9 co-culture, which only took 8 days.  After two rounds of 










Figure 2.3. Derivation of hESC-derived EPCs via mouse stromal M2-10B4 co-culture. A. Scheme 
diagram on the M2-10B4 co-culture protocol. H1 colonies were co-cultured with mitomycin-C treated 
M2-10B4 cell culture for 13 days. Magnetic sorting was then performed to obtain CD34+ cells. B. M2-
10B4 culture at day 4. C. Co-culture of H1 and M2-10B4 at day 13. D. EPCs at day 3 after CD34+ 
magnetic sorting on fibronectin-coated dish.  E. H1 derived EPCs via M2-10B4 co-culture expressed 
endothelial lineage surface markers: CD34+, CD31+, Flk1+ before and after sorting process via flow 
cytometry. EPC derived from H1 co-cultured with M2-10B4 cells express CD45 markers albeit at low 
level, which is a marker for hematopoietic lineage. F. Expression of von Willebrand Factor as shown by 
immunostaining (Left to right: phase-contrast, GFP expression, hoechst nucleus staining). G. hESC-
EPCs form tubule-like formation when seeded onto a matrigel-coated dish.  
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The expression of EPCs markers were tested via flow cytometry (Fig. 
2.3E). We observed that the percentage of CD34
+
 cells varied from 5-20% 
prior to sorting. We also noticed that the co-expressions of the CD34 marker 
and other EPC markers such as CD31 and Flk1 were lower compared to OP9 
co-culture derived EPCs. Furthermore, we noted that the sorted CD34
+
 cells 
had a higher expression of the CD45 marker, compared to the OP9 co-culture 
derived EPCs.  
 
Figure 2.4. H9 hESC line-derived EPCs via mouse stromal M2-10B4 co-culture. 
A. Co-culture of H9 and M2-10B4 at day 6. B. EPCs at day 6 after CD34
+
 magnetic 
sorting on fibronectin-coated dish. C. Flow cytometry showing expression of CD34 
together with other EPCs markers: CD31, Flk1 and CD144 before and after MACS. 
D. Expression of von Willebrand Factor as shown by immunostaining (Left to right: 





We further tested the expression of von Willebrand Factor (vWF), a 
glycoprotein constitutively produced in the endothelium, in the sorted CD34
+
 
cells via immunostaining, and the results were positive (Fig. 2.3F). These cells 
could also form tube-like formations when seeded onto matrigel (Fig. 2.3G). 
However, by observing the matrigel tubulogenesis results qualitatively, we 
noticed that tubulogenesis was more efficient for the cells that were produced 
via OP9 co-culture, compared to the M2-10B4 co-culture method. We also 
tested this method using H9 and iPS cells, and we obtained EPCs with similar 
characteristics (Fig. 2.4 – 2.5).  
 
Figure 2.5. iPS cells-derived EPCs via mouse stromal M2-10B4 co-culture. A. Co-
culture of iPS colonies and M2-10B4 at day 9. B. EPCs at day 6 after CD34
+
 magnetic 
sorting on fibronectin-coated dish.  C. Expression of von Willebrand Factor as shown by 
immunostaining (Left to right: phase-contrast, GFP expression, hoechst staining). D. 




2.3.1.3 Non-stromal 2-D differentiation method 
The above co-culture method can recreate native stem cell niches, thus 
providing an inductive environment for the differentiation of hESCs. 
However, contamination of animal cells is one concern which needs to be 
tackled before this method can be used in clinical settings. Thus, we opted for 
a non-stromal 2-D differentiation method (Fig. 2.6A) described by Wang et 
al
130
. After changing the medium from mTeSR to the differentiation medium, 
the H1 cells started to spread out, leaving the colonies and filling the entire 
culture dish. Interestingly, they also formed root-like structures like those 







 cells after 2 rounds of MACS (Fig. 
2.6C). The EPCs generated via the 2-D differentiation method had a similar 
expression of surface markers as those produced by the OP9 co-culture 
method. After sorting, most of the CD34
+
 cells also co-expressed CD31, Flk1 
and VE-Cadherin, but not CD45 (Fig. 2.6D).  
By using the same method, we can also generate iPS cell-derived EPCs 
(Fig. 2.7A-B). The flow cytometry results reveal some differences between 
the hESC and iPS cell-derived EPCs (Fig. 2.7C). For H1-derived EPCs, the 
purity of CD34
+
 cells after 2 rounds of MACS was higher (˃90%). Besides, 
most of the CD34
+







(approximately 90%). However, in the case of iPS cell-derived EPCs, 
approximately 50-55% of the cells co-expressed these markers. Yet, these 




Figure 2.6. H1 hESC-derived EPCs via 2-D differentiation method. A. Protocol 
for 2-D differentiation method. H1 medium was changed to differentiation medium 
when H1 culture reached confluency. After 10 days, MACS was performed to obtain 
CD34
+
 cells. B. H1 differentiation at day 6. C. Sorted CD34 on fibronectin-coated 
dish. D. Flow cytometry of the cells before and after sorting via MACS of the 
different EPCs markers. Most of the CD34
+
 cells co-expressed CD31, Flk1, and VE-







Figure 2.7. iPS cells-derived EPCs via 2-D differentiation method. A. Image 
showing iPS at day 6 of differentiation. B. Sorted CD34
+
 cells plated on fibronectin 
coated plate. C. Flow cytometry of the cells before and after sorting via MACS of the 
different EPCs markers. Lower percentage of CD34 as well as other markers as 
compared to hESC-EPCs was observed before and after MACS.  
   
2.3.1.4 Human iPS cell-derived EPCs via embryoid bodies formation 
A protocol has been published to use well-established human ES cell lines to 
differentiate mesoderm cells in EBs into endothelial precursors
132
. We tested 
whether the protocol could be used to derive endothelial precursors from 
early-passage human iPS cells (around p10). EBs formed by human iPS cells 
cultured on low attachment dishes were plated onto a matrigel-coated culture 
dish and treated with BMP4 (day 0-7), Activin A (day 1-4), FGF2 (day 2 
onwards), VEGF (day 4 onwards), and SB431542, a TGF-β inhibitor, (day 7 
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onwards) for 2 weeks (Fig. 2.8A-B). After the EB was replated, we observed 
the root-like structure again during the differentiation process (Fig. 2.8B 
right). From one 10-cm dish of EB (i.e from one well of a 6-well plate iPS 




 cells with just one 
round of MACS (Fig. 2.8C).  
The percentage of EPCs markers before sorting was highest using this 
method compared to other methods (Fig. 2.8D). Fluorescence-activated cell 
sorting (FACS) analysis revealed that the generated cells were a mixed 
population of cells containing ≥ 20% cells positive for CD34, a hematopoietic 
stem cell marker. The mixed population of cells co-expressed endothelial cell 
markers, including CD31 (17.60%), Flk1 (8.13%), and VE-cadherin (10.71%), 
but had a low expression level of the CD45 hematopoietic marker (1.44%).  
After undergoing immunomagnetic separation to enrich the CD34
+
 
cells and promote cell expansion in an endothelial growth medium, flow 
cytometric analysis showed that ≥ 95% of cells at passage 2 were CD34-
positive (Fig. 2.8D). A majority of the purified CD34
+
 cells were also positive 
for CD31 (81.29%). While a majority of the purified CD34
+
 cells were also 
positive for CD31 (81.29%), approximately 21% of the CD34
+
 cells co-
expressed Flk1, 48% expressed VE-cadherin, and only 8.98% of these cells 
were CD45
+
. Since CD34 is expressed on both immature EPCs and mature 
circulating endothelial cells, we also examined the expression of CD133, a 
stem cell marker restricted to immature EPCs, on the sorted cells, and found 
that 30% of the cells were CD133-positive (Fig. 2.8E). As a negative control, 
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human fibroblasts used to generate iPS cells were tested and showed no 
CD133 expression (0.76%). 
Furthermore, many of the iPS cell-derived cells were vWF-positive 
(Fig. 2.9A) and CD31-positive (Fig. 2.9B), as shown by immunostaining. 
Biological and functional characterization showed that the derived cells were 
able to incorporate the DiI-labelled acetylated LDL (Fig. 2.9C) and readily 
formed tubule-like structures upon seeding onto matrigel (Fig. 2.9D). 
Therefore, we use the term iPS-EPCs to refer to all endothelial lineage cells 




Figure 2.8. Generation of EPCs from human iPS cells via EB method. A. 
Generation of EPC from iPS. Confluent iPS colonies were scraped to generate EBs. 
After 4days, the EBs were replated onto matrigel-coated dish and cultured for 10 
days. CD34
+
 cells were then harvested and maintained on fibronectin-coated dish. B. 
Left to right: EB, 1 day after the EBs were replated, differentiation day 10. C. EPCs 
at passage 3 after MACS. D. Flow cytometry before and after the magnetic cell 
sorting to show expression of EPCs markers CD34, CD31, Flk1 and VE-cadherin, 
and less expression of hematopoietic marker CD45. E. Expression of CD34 and 
CD133 “stemness” markers on sorted for CD34+ cells. Human fibroblast were used as 




Figure 2.9. Characterization of iPS cells-derived EPCs. A. Expression of von 
Willebrand Factor as shown by immunostaining (left to right: phase contrast, GFP, 
Hoechst staining). B. Expression of CD31 as shown by immunostaining (left to right: 
phase contrast, GFP, Hoechst staining). C. iPS-EPCs could uptake AcLDL. Phase 
contrast (Left) and red fluorescence (Right) images of Ac-LDL taken up by the 
generated iPS-EPCs. Arrow shows DiI-Ac-LDL being taken up by the cells.  D. iPS-








2.3.2 Tumor tropism of iPS-EPCs 
2.3.2.1 Homing of hPSC-EPCs to 4T1-luc orthotopic breast cancer model 
To non-invasively examine the in vivo distribution of hPSCs-derived EPCs in 
mice over time following systemic injection, we employed IVIS dual color-
imaging technology. This system detects and captures luminescent signals 
from 4T1-luc cells and fluorescent signals from DiR-labelled iPS-EPCs. Prior 
to animal experiments, labeling optimization of iPS-EPCs by DiR was 
performed. The cells can be efficiently stained with DiR at a concentration of 
50 μg/ml for 30 min at 37oC, a process which in having 95.93% of the cells 
positively and uniformly labeled as indicated by the sharp peak (Fig. 2.10A).  
To examine the in vivo tumor tropism of the generated hPSCs-EPCs, 
we established two mouse breast cancer models in athymic Balb/c nude mice: 
an orthotopic breast cancer model generated by subcutaneous injection of 
luciferase-expressing mouse 4T1 breast cancer (4T1-luc) cells onto the 
mammary fat pad (Fig. 2.10B) and a breast cancer lung metastasis model 
generated by intravenous injection of 4T1-luc cells via the tail vein (Fig. 
2.10C). 
We first tested in vivo tumor tropism of iPS-EPCs in the orthotopic 
breast cancer model (Fig. 2.11). After labeling iPS-EPCs with the near-infrared 
fluorescent dye DiR, we injected the cells into the tumor-bearing mice through 
tail vein injections at day 7 post-tumor inoculation. The Xenogen IVIS Imaging 
System was employed for non-invasive dual-color in vivo imaging to 
longitudinally monitor the distribution of the labeled iPS-EPCs at days 0, 1, 3, 
7, and 14 post-EPC injection in the same sets of animals. Whole-body 
59 
 
bioluminescence imaging showed that tumors grew quickly around the 
inoculated mammary fat pad during the 21-day observation period, and 
luciferase signals outside the primary tumor region were observed at day 21 
post-tumor inoculation, indicating metastasis (Fig. 2.11A). 
 
Figure 2.10. Dual in vivo imaging system. A. DiR labeling optimization of EPCs. 
EPCs can be efficiently labeled with DiR at concentration 50μg/ml for 30min at 37oC. 
B. Schematic illustration of the dual in vivo imaging system utilizing both 4T1luc and 
DiR-labeled EPC in mammary pad model. Breast cancer 4T1luc cells are inoculated 
into mammary fat pad of the mice. One week after the tumor inoculation, DiR-labeled 
EPCs are introduced into the mice via tail vein injection. IVIS imaging are carried out 
at day 1, 3, 7, and 14 post tail vein injection. C. Protocol for tumor tropism study in 
lung metastatic model. The 4T1luc cells are inoculated into the mice via tail vein 
injection. Three days after the tumor inoculation, DiR-labeled EPCs are introduced 
into the mice via tail vein injection. IVIS imaging are carried out at day 1, 3, 7, and 





Figure 2.11. Tumor tropism of iPS cells-derived EPCs in the 4T1 orthotopic mouse 
model of breast cancer. A. Whole animal images of Balb/c nude mice of injected with DiR 
labeled – iPS-EPCs alone, and DiR-iPS-EPCs with 4T1luc breast cancer cells. EPCs can be 
seen migrating toward primary tumor site (mammary pad region) as early as day 1 post tail 
vein injection. After 14 days, more cells are migrating towards the tumor site. B. Percentage 
distribution of iPS-EPCs in the primary tumor region over the whole body. Overall average of 
12% in the tumor-bearing mice as compared to 3% in animal without tumor over time. There 
values are statistically significant different as tested by one-way ANOVA (p=0.03, 0.026, 
0.006,0.021 for day 1, 3, 7, and 14 respectively. C. Ex vivo image of the different organs: 
brain, lungs, heart, spleen, liver, intestines, kidneys, spinal cord, femur, mammary pad (left to 
right). Red circle indicates strong DiR signals in the mammary fat pad of tumor-bearing 
animals. No singles were detected in the same region in controls.  
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Whole-body DiR fluorescence imaging showed that tail vein-injected 
iPS-EPCs were initially distributed predominantly to the lung region. One day 
after tail vein injection, the size of the DiR signal-positive area in the thoracic 
region significantly increased. Meanwhile, we observed significantly 
increased DiR signals in the tumor inoculation site in tumor-bearing mice 
(Fig. 2.11A). The DiR signals in this region were significantly higher, 
compared with those in mice without tumors, and remained high for at least 14 
days, although the overall DiR signal intensity reduced from day 3 onwards 
(Fig. 2.11A). On average, approximately 12% of the injected iPS-EPCs homed 
into the 4T1-luc tumor cell inoculated mammary pad region as calculated by 
the percentage of DiR signal in the region over the whole body signal (Fig. 
2.11B). 
At day 14, the mice were sacrificed and ex vivo images of different 
organs were taken (Fig. 2.11C). Here, we can scrutinize the metastases that 
have occurred in the mice, manifestations which could not be detected by 
whole-body imaging alone. The luc signals indicated that the 4T1 tumor cells 
metastasized to the lungs, spleen, liver, intestines, spinal cord and femur. 
There were overlaps of luminescent (luc) and fluorescent (DiR) signals in the 




Figure 2.12. In vivo migration of hESC-EPCs toward 4T1 breast cancer cells in 
4T1 orthotopic immunocompromised NSG mice. A. EPCs migrated toward 
primary tumor site as early as day 1 post tail vein injection. After 14 days, more cells 
are migrating towards the tumor site. B. Percentage distribution of iPS-EPCs in the 
primary tumor region over the whole body. Statistical tests showed significant 
difference in the values between the two groups (p=0.021, 0.0009, 0,005 for day 1, 7 
and 14 respectively). C. Ex vivo image of the solid tumor mass shows overlap of 
luminescent luc and fluorescent DiR signals. This implies that EPCs have migrated to 
the tumor.  
 
We also tested the in vivo distribution of hESC-derived EPCs in 
immune-compromised NSG mice bearing the 4T1-luc tumor in the mammary 
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pad. As early as day 1 post-intravenous injection, the DiR fluorescent signal 
can be seen around the mammary pad where the 4T1 tumor had been 
inoculated a week before (Fig. 2.12A). Most cells were trapped in the liver 
and lung area. Over time, more EPCs migrated to the 4T1 primary tumor site. 
More than 20% of cells migrated to the mammary pad region, based on the 
percentage of DiR signal in that region over the whole body signal at day 14 
(Fig. 2.12B). The tumor ex vivo image reveals that there was an overlap of 
signals between the fluorescent DiR and luminescent luc, indicating that EPCs 
home to 4T1 tumor cells (Fig. 2.12C). Thus, we showed that both iPS cells 
and hESC derived EPCs have tumor homing properties.  
2.3.2.2 Homing of iPS-EPCs to breast cancer lung metastasis model 
Next, we tested in vivo tumor tropism of iPS-EPCs in the breast cancer lung 
metastasis model (Fig. 2.13). We injected the DiR-labeled iPS-EPCs into the 
tumor-bearing mice through tail vein injections at day 3 post-tumor inoculation. 
Whole-body bioluminescence imaging showed that tumor growth became 
detectable at day 10 post-tumor inoculation (day 7 post-EPC injection). By 
day 17 post-tumor inoculation, cancer cell dissemination to other organs was 
observed (Fig. 2.13A). Whole-body DiR fluorescence imaging showed that 
tail vein-injected iPS-EPCs were distributed predominantly to the lung region 
and decreased over time from day 1 to day 14 post-EPC injection (Fig. 
2.13A). When compared with DiR signals in normal Balb/c mice that were 
injected with only the labeled iPS-EPCs without 4T1 tumor cell inoculation, it was 
found that  DiR signals in the tumor-bearing mice were relatively stronger in 
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the lung region and a statistically significant difference between the two 
groups of mice was observed at day 14 (Fig. 2.13B). 
 
Figure 2.13. Tumor tropism of iPS cells-derived EPCs in the 4T1 breast cancer 
lung metastasis model. A. Whole body images showing the EPCs are trapped in the 
lungs regions, for both the control group and tumor bearing animal group. B. The DiR 




2.3.2.3 Tumor tropism of iPS-EPCs to 2M1 invasive glioma model 
We also investigated the distribution of EPCs after intratumor injection into a 
2M1 invasive glioma orthotopic tumor model (Fig. 2.14A). In the primary 
tumor site, we can see that the EPCs infiltrated the tumor mass, migrating 
towards the tumor vessels (Fig. 2.14B-C). More importantly, EPCs can be 
seen infiltrating successfully into the tumor blood vessels, as shown in the 
yellow circle (Fig. 2.14D). Interestingly, EPCs can also be found in tumor 
satellites located in the lateral ventricle, away from the primary tumor site 
(Fig. 2.15A-C). This implies that EPCs can target secondary metastatic tumor 




Figure 2.14. Biodistribution of EPCs 
in intracranial 2M1 glioma model at 
primary tumor mass. A. Protocol of the 
biodistribution experiment on mice 
glioma model. B. Primary DiO-labeled 
2M1 tumor mass, infiltrated by DiI-
labeled EPCs. White line: tumor border 
region. C. Magnified view of B, showing 
the tumor blood vessels. The EPCs 
infiltrate the tumor region, toward the 
tumor blood vessels. White line: tumor 
border region, yellow lines: the tumor 
blood vessels. D. EPCs incorporated into 
the tumor blood vessel (yellow line). 




2.3.3 Effects of iPS-EPCs on tumor development and metastasis  
The potential role of EPCs in promoting tumor growth is a concern when these 
cells are used as delivery vehicles for cancer therapy
138
. To investigate 
whether iPS-EPCs alone affect tumor progression and metastasis in the above 
orthotopic breast cancer model, we injected iPS-EPCs intratumorally at day 7 
post-inoculation of 4T1-luc breast cancer cells (Fig. 2.16A). Intratumor 
injections of iPS cells, fibroblasts, and PBS were included as controls. Another 
well-established cellular delivery vehicle, iPS-NSCs, was also injected 
intratumorally for comparison (Fig. 2.16A). The tumor progression is similar 
throughout the different groups and comparable with the biodistribution 
Figure 2.15. Biodistribution of EPCs 
in intracranial 2M1 glioma model at 
secondary tumor foci. A. DiO-
labeled 2M1 cells found at the lateral 
ventricle, infiltrated by DiI-labeled 
EPCs. B. Magnified view of A. EPC 
can target secondary tumor sites. C. 
Different secondary tumor site, where 
EPCs were also found.  
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results (Fig. 2.11). The average tumor signals of the four groups were similar 
up to day 7 (Fig. 2.16B). Up to day 14, the tumor volume for the iPS-EPC 
group remained low compared to the rest of the groups.  However, by day 21 
the luc signal is comparable among all the groups. However, this can be due to 
the deaths of animals from the iPS group, which might explain the sudden 
drop in the luc signal at day 21 (Fig. 2.16B). The animals were sacrificed at 
day 21 and their organs were collected for ex vivo bioluminescence imaging 
(Fig. 2.17A). The 4T1-luc signal intensities in the examined organs were 
comparable in all groups (Fig. 2.17B). Although the tumor signal in the 
intestine was higher in the iPS-EPC group compared to the other groups, 
statistical analysis revealed that the differences were not significant.   
Possible effects of iPS-EPCs on tumor development were further 
investigated in the breast cancer lung metastasis model. Taking advantage of 
the quick animal death in this model, we focused on the survival of tumor-
bearing animals in this experiment. The mice were separated into five groups: 
PBS, iPS, human fibroblast, iPS-NSCs and iPS-EPCs. The different cells were 
injected intravenously via the tail vein 3 days after intravenous injection of 
4T1-luc cells. Tumor growth was monitored by whole-body bioluminescent 
imaging of 4T1-luc cells. Whole body imaging of three mice from each group 
was shown as representatives (Fig. 2.18A). The bioluminescence intensities, 
indicative of tumor volume, demonstrated that there were no significant 
differences among the PBS group, iPS cell group, and iPS-EPC group, although a 
significantly higher level of 4T1-luc signal was observed in the HFF group at day 
21 (Fig. 2.18B). 
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Mice started to die at day 17 in all groups. The median survival times were 
26.2, 26.8, 25.6, and 27.6 days for the PBS, fibroblast, iPS cell and iPS-EPC 
groups respectively. There was no statistically significant difference among 
the four groups in survival rate (p = 0.946) (Fig. 2.18C). Our findings indicate 
that iPS-EPCs did not obviously promote tumor growth in the 2 tested tumor 
models. 
 
Figure 2.16. Effects of iPS-EPCs on 4T1 tumor development and metastasis in 
the 4T1 orthotopic mouse model of breast cancer. A. Whole body imagings of 3 
representative animals from each groups: PBS, HFF, iPS and iPS-EPCs. Similar 
tumor progression as shown by the bioluminescent signals. Metastases can be 
detected at 2 weeks time point onwards. B. Tumor volume average from each groups. 






Figure 2.17. Effect of iPS-EPCs on tumor development and metastasis in 4T1 
mammary pad model. A. Representative ex vivo images of different organs 
collected at day 21 post-intratumor injection: lungs, liver, spleen, kidneys, heart, 
brain, intestines, spinal cord, femur, primary tumor mass (from left to right). Images 
on iPS-EPCs group showed comparable metastatic progression as the other control 
groups. B. Luc signal of different organs. ANOVA statistics revealed that no 






Figure 2.18. Effect of iPS-EPCs on 4T1luc tumor development in the 4T1 breast cancer 
lung metastasis model. A. Whole body imagings of 3 representative animals from each 
groups: PBS, human foreskin fibroblast (HFF), iPS and iPS-EPCs. Bioluminescent signal of 
4T1luc show the tumor development over time after tail vein injection of different cells. At 
day 21, animals from iPS-EPCs group show less intense signal and less metastatic indication. 
B. Average tumor volume in each group represented by the bioluminescent luc signal. At day 
21, there is a statistically significant difference in the luc signal among the groups (p=0.004). 
Value in HFF group is significantly different from PBS, iPS-NSCs and iPS-EPCs groups 
(p=0.00301, p=0.0007 and p=0.001 respectively). C. Survival curves of tumor-bearing mice. 
No statistically significant difference in the survival rates among the groups (p=0.946).  
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2.3.4 Genetic modification of EPCs 
 
Figure 2.19. Genetic modifications of EPCs. A-B. Baculovirus transduction in EPCs 
(A.) Flow cytometry showing the percentage of EGFP in iPS-EPCs after transduction 
with baculoviral vector expressing EGFP. (B.) Cells expressing green eGFP after 
transduction with baculovirus (left) and the phase-contrast picture (right). C. H1-BV-
RMCE-EGFP in M2-10B4 co-culture. H1 colonies maintained the EGFP expression 
throughout the differentiation process. D-E. H1-BV-RMCE-EGFP in 2D EPC 
differentiation. (D.) H1 colonies, CD34
+
 cells after sorting and replating on fibronectin 
coated dish expressed EGFP as shown by the picture (E.) and flow cytometry of EGFP. 
73 
 
A high level of permissiveness to gene transfer is a vital requirement that 
allows the use of cellular vehicles for cancer gene therapy. Baculoviral 
vectors, which are derived from an insect virus Autographa californica 
multiple nucleopolyhedrovirus, emerge as a potentially safe class of gene 
delivery vectors due to their inability to replicate or cause toxicity in 
mammalian cells
125
. We showed that baculoviral vectors are capable of 
transducing iPS-EPCs. By using a baculoviral vector which expresses EGFP, 
we showed that 85.93% of the cells are EGFP positive, 60.99% of which are 
CD34
+
 (Fig. 2.19A). The expression of EGFP in the cells were strong and 
bright (Fig. 2.19B).  
Recently, our lab has successfully established a system to genetically 
modify hESCs specifically at AAVS1 locus
139
. The system involves a two-step 
process combining homologous recombination with baculovirus-mediated 
(BV) Cre-RMCE (Cre recombinase-mediated cassette exchange). The 
generated master loxP-hESC line produced in the first step provides rich 
opportunities for readily introducing transgenes into AAVS1 through efficient 
BV-Cre-RMCE. By using the two-step process combining homologous 
recombination with BV-Cre-RMCE, we can produce EGFP expressing EPCs 
from the loxP-hESC line (Fig. 2.19C-D). The stable EGFP-expressing H1 
colonies could be differentiated into EPCs. In Fig. 2.19C, we see that the H1 
colonies maintain their EGFP expression throughout the M2-10B4 co-culture 
period. The EGFP expressing H1 could also be differentiated via the 2-D 
differentiation method without any loss of EGFP expression (Fig. 2.19D). 
After sorting, all the CD34
+
 cells expressed EGFP (Fig. 2.19D), and this was 
further confirmed by flow cytometric analysis (Fig. 2.19E).    
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2.3.5 EPCs therapeutic effects 
2.3.5.1 iPS-EPC expressing CD40L impede tumor development in a breast 
cancer lung metastasis model 
To assess the prospects of iPS-EPCs as the cellular delivery vehicle for 
therapeutic genes, we transduced the cells with baculovirus expressing CD40L 
gene, a member of the tumor necrosis factor (TNF) gene family
108
. Flow 
cytometric analysis indicated that up to 82.23% of iPS-EPCs could be 
transduced to express detectable levels of CD40L (Fig. 2.20B). The 
transduced cells were injected via the tail vein into athymic Balb/c nude mice 
bearing 4T1-luc breast cancer lung metastases. Tumor growth was monitored by 
whole-body bioluminescent imaging of 4T1-luc cells. Figure 2.20A shows 
representative 4T1 cell-bearing mice from different groups at 4 different time 
points. The bioluminescence intensities, indicative of tumor volume, demonstrate 
that the inhibitory effect of CD40L-expression iPS-EPCs on tumor growth was 
visible at day 14. Compared to the control groups, a statistically significant lower 
level of 4T1 cell-related luciferase signals was observed in the treated mice by 
day 21 post-tumor inoculation (Fig. 2.20C). Survival of the tumor-bearing mice 
in this group was significantly prolonged, and this was attributed to the effect of 
CD40L-expression of iPS-EPCs (Fig. 2.20D). On day 35, while all the mice in the 
three control groups had died, 60% of animals in the treated group were still alive 
(Fig. 2.20E). The median survival times were 25 to 29 days in the control 
groups, and 34 days in the treated group. The difference was statistically 
significant (p = 0.004 in Holm-Sidak test). There was no statistically 










Figure 2.20. Therapeutic effects of CD40L-expressing iPS-EPCs in the 4T1 
breast cancer lung metastasis model. A. Bioluminescent images of tumor growth in 
representative animals from each group at days 1, 7, 14 and 21 after iPS-EPC 
injection. Tumor signal is weaker in animals belong to iPS-EPCs-CD40L. B. CD40L 
expression in iPS-EPCs after transduction with a baculoviral vector containing 
CD40L gene under the control of the CMV promoter. C. Quantitative analysis of 
bioluminescent signals. Up to week 2, the average tumor signal is comparable. At day 
21, there is a significant difference in the tumor volume of iPS-EPCs-CD40L group 
against the other control groups (P<0.001). Bar: s.d. * p < 0.05 vs the group of mice 
injected with iPS-EPC/BV-CD40L by analysis of variance. D. Survival curves of 4T1 
tumor-bearing mice. CD40L expression prolongs the life of 4T1 tumor-bearing 
mice.The Gehan-Breslow statistic for the survival curves is greater that would be 
expected by chance; there is a statistically significant difference between survival 
curves (P = 0.004). E. Graph showing the values of median survival times of animals 
from different groups. Statistical analysis by the log rank test reveals the significantly 
improved survival in the group of mice injected with iPS-EPC/BV-CD40L as 
compared with other groups. 
   
2.3.5.2 iPS-EPCs expressing HSV-tk 
We also tested the therapeutic effect of EPCs expressing the HSV-tk suicide 
gene. According to the images of the whole animal (Fig. 2.21A) and the 
average luc signal reading (Fig. 2.21B), the HSV-tk+GCV group has a lower 
tumor burden compared to the control groups (PBS, EPC alone, EPC-HSVtk 
without GCV) at day 14 and 21. However, when we ran the one way ANOVA 
tests, it was found that these differences are not statistically significant. 
Furthermore, the survival of the mice is only slightly prolonged and the 
survival curve (Fig. 2.21C) shows no significant differences among the groups 




Figure 2.21. Therapeutic effect of iPS-EPCs expressing HSV-tk in 4T1luc lung 
metastatic Balbc/nude mice. A. Whole images of 3 representative animals from 
each group: PBS, iPS-EPCs, iPS-EPCs express empty baculoviral vector, and iPS-
EPCs express baculoviral vector containing HSVtk gene. B. Tumor volume of the 
different groups of mice as shown by the luc signal. C. Survival curve of the animals. 
The Gehan-Breslow statistic for the survival curves is not great enough to exclude the 
possibility that the difference is due to random sampling variability; there is not a 
statistically significant difference (P = 0.084).  
 
2.3.5.3 iPS-EPCs expressing Isthmin 
Isthmin (ISM) is a 60kDa anti-angiogenesis protein that is secreted at high 
levels in the hindbrain-midbrain organizer in Xenopus embryos
126, 127
. We 
investigated the cancer therapeutic effect of this anti-angiogenic protein when 
it is expressed through EPCs. We constructed a baculoviral vector which 
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expresses mouse isthmin (BV-CMV-mISM-WPRE). The mouse isthmin 
plasmid was generously given by Prof Ge Ruowen’s lab (Department of 
Biological Sciences, National University of Singapore).  
BV-CMV-mISM-WPRE was tranduced into EPCs and its expression 
was confirmed through PCR (expected band size of 485 bp) (Fig. 2.21A). We 
then proceeded to test the anti-angiogenic activity of isthmin in vitro via 
matrigel tubulogenesis experiments (Fig. 2.21B-F). Figure 2.21B shows the 
results of matrigel tubulogenesis using EPCs which have been transduced with 
BV-CMV-EGFP-WPRE. We can see that the tubulogenesis was not affected, 
compared to the control set (Fig. 2.21F). Likewise, when we used the 
conditioned medium of EPCs transduced with EGFP, and ran the 
tubulogenesis experiment using freshly prepared EPCs, the tubulogenesis was 
not affected too (Fig. 2.21C). Unfortunately, when we tested the tubulogenesis 
of EPCs transduced with BV-CMV-mISM-WPRE (Fig. 2.21D) or fresh EPCs 
with a conditioned medium of EPCs transduced with isthmin (Fig. 2.21E), the 
tube-like formations were not affected as well.  
Interestingly, when HUVEC is transduced with isthmin before matrigel 
tubulogenesis was performed, the same results were observed whereby the 
tubulogenesis was not affected. However, when the isthmin-conditioned 
medium was concentrated 100× and used for the matrigel tubulogenesis for 
fresh HUVECs, tubulogenesis failed to occur (data not shown, performed in 
Prof Ge Ruowen’s lab, DBS, NUS). Thus, we proceeded to test whether 






Figure 2.22. Therapeutic effects of EPCs encoding mIsthmin. A. In vitro 
expression of BV-CMV-mISM-WPRE in iPS-induced EPCs. B. matrigel 
tubulogenesis performed using EPCs transduced with BV-CMV-EGFP-WPRE in 
fresh EPC medium (left: phase contrast, right: EGFP expression). C. Negative 
control; Fresh EPCs in fresh EPC medium. D. matrigel tubulogenesis performed 
using EPCs transduced with BV-CMV-mISM-WPRE in fresh EPC medium. E. 
Matrigel tubulogenesis performed using fresh EPCs in BV-CMV-EGFP-WPRE 
transduced EPCs conditioned medium. F. Matrigel tubulogenesis performed using 
fresh EPCs in BV-CMV-mISM-WPRE transduced EPCs conditioned medium. G. 
Tumor volume of the different groups of mice as shown by the luc signal. One way 
ANOVA tests showed no significant difference among the groups. H. Survival curve 
of the animals. The Gehan-Breslow statistic for the survival curves is not great 
enough to exclude the possibility that the difference is due to random sampling 
variability; there is not a statistically significant difference P=0.401. 
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The 4T1-luc cells were injected intravenously to create lung metastatic 
model mice. Three days later, 5×10
5
 iPS-EPCs transduced with BV-CMV-
Isthmin-WPRE were injected intravenously into the tumor bearing mice. As 
controls, PBS, iPS-EPCs, and iPS-EPCs transduced with empty baculoviral 
vectors were injected into the mice. From both the average luc signal reading 
(Fig. 2.21G) and the survival rate of the animals (Fig. 2.21H), we were not 
able to observe any obvious therapeutic effect in the tumor-bearing mice.  
2.4 Discussion 
2.4.1 Derivation of EPCs 
The hPSCs provide an unlimited source of cells for cell therapy. Moreover, 
hPSCs provide a method of studying basic human developmental biology 
without trespassing on ethical boundaries. During embryogenesis, the 
developmental progression of hematopoietic and endothelial lineages is 
closely associated. Thus, endothelial and hematopoietic progenitors share 
common markers such as CD34, CD31 and Flk1
79
. Hematopoietic cells were 
then distinguished from its endothelial counterpart by the expression of CD45, 
a common leukocyte antigen which is not expressed in endothelial cells
80, 130
. 
Our EPCs expressed CD34, CD31 and Flk1 but not the CD45 hematopoietic 
marker. After further culture in an EGM2 endothelial cell medium, these cells 
were positive for other characteristics associated with EC lineage markers 
such as VE-cadherin, von Willebrand Factor, uptake of Ac-LDL. In addition 
to this, the cells could form tubular structures when seeded onto matrigel
79, 83
. 
In our study, we initially utilized the mouse stromal cells, OP9 and 
M2-10B4, to produce EPCs from hESC and iPS cells. These cells have been 
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shown to support hematoendothelial differentiation of hESCs due to 
soluble/secreted factors that are important for hematoendothelial 
development
140
. Our generated EPCs via these co-culture methods were 
comparable to previous reports 
141, 142
. However, the M2-10B4 co-culture 
process took a longer time to generate EPCs (13 days instead of 8 days for 
OP9 co-culture). Moreover, although Tian et al. showed that CD45
+
 cells 
started to appear only in approximately 17-21 days of culture, we noticed that 
our produced EPCs expressed the CD45 marker earlier (we harvested at day 
13-14). This CD45 expression is higher as compared to that of the OP9 co-
culture derived EPCs. Furthermore, by observing the matrigel tubulogenesis 
results qualitatively, we noticed that tubulogenesis was more efficient for the 
cells that were produced via OP9 co-culture as compared to the M2-10B4 co-
culture. Thus, we conclude from our studies that OP9 co-culture is more 
robust in producing EPCs than M2-10B4 co-culture.     
The co-culture methods can recreate native stem cell niches, thus 
providing an inductive environment for the differentiation of hESCs. The 
ability to modify stromal cells to express various components that may 
promote or inhibit lineage-specific differentiation also provides a useful means 
to define specific niche factors that regulate human hematopoiesis
137, 140
. For 
example, M2-10B4 stromal cells expressing Wnt1 or Wnt could enhance EPC 
differentiation from hESCs
137
. However, avoidance of xenogeneic tissue, such 
as murine cells that are used for the maintenance of undifferentiated hPSCs or 
stromal cell lines that are commonly utilized to induce differentiation, is 





Interestingly, in all the differentiation methods, we observed similar 
morphological changes during the differentiation process. The initial button-
like structure of H1 or iPS grew into root-like structure be it in the stromal co-
culture or stromal-independent culture. Previously, our lab has investigated the 
localization of CD34
+
 cells in OP9 co-culture via live CD34
+
 cell 
immunostaining of differentiated hESC colonies. We found that the main 
population of CD34
+
 cells is located in the root-like structures that penetrate 
the OP9 portion of the co-culture. Thus, since we also observed similar 
structures in the other methods, we speculate further that these structures 
might mimic the hematopoietic niche in the bone marrow. However, further 
studies need to be done to prove this.  
Our produced EPCs both from iPS cells and hESCs express markers in 
similar manners. However, in the 2-D differentiation method, we noted some 
differences in between the hESC and iPS cell-derived EPCs in terms of the 
purity of CD34
+
 cells after sorting and the co-expressions of the EPCs 
markers. Such differences have also been reported previously
143, 144
. White and 
colleagues previously have shown that there are differences in the gene 
expression between ECs derived from hESC and iPS cells, notably genes 
related cell cycle and adhesion 
92
. However, despite the gene expression 
heterogeneity, they concluded that ECs derived from both pluripotent cell 
types behave very similarly 
92
. 
The yield and purity of EPCs derived using EB method was superior 
compared to the other methods. The differentiation medium was supplemented 
with BMP4, Activin A, bFGF, VEGF cytokines and TGF-β inhibitor 
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(SB431542). BMP4 has been shown to promote mesodermal lineage 
differentiation from hPSCs 
88, 143
. Addition of VEGF and bFGF has been 
shown to enhance the expression of CD34 during the hematoendothelial 
differentiation 
143
.  Studies have shown that TGFβ pathway is important for 
hematopoietic development and that TGFβ inhibition maintains the 
proliferation and identity of endothelial cells in vitro 
132, 140
. 
CD133 (AC133, prominin-1) is a transmembrane domain cell surface 
glycoprotein which serves as a marker of asymmetric division, lineage 
plasticity, tumor cell dormancy and inherent embryonic gene expression 
80, 145
. 
CD133 have been repeatedly used as a marker for early endothelial lineage 
cells 
81, 82, 146
. EB derived EPCs expressed CD133 stem cell marker indicating 
that they are still in early phase of endothelial differentiation. Moreover, these 
iPS cell-derived cells are positive for the above-mentioned endothelial 
progenitor markers and display other characteristics associated with EPCs, 
including VE-cadherin, von Willebrand Factor, uptake of AcLDL and 
formation of tubule structure upon seeding onto matrigel 
79, 83
.  
In our study, the produced EPCs could maintain the markers and 
properties only for up to 5 passages. However, the self-renewing hPSCs 
possess unlimited proliferation capacity, thus can be used as a reliable source 
to generate vast amounts of human EPCs for cell therapeutics purpose. The 
use of human iPS cells especially garners attention since it can avoid the 
ethical concerns regarding its derivation, in contrast to the hESC counterpart.   
iPS cells are a unique type of biological material that can be used to 
generate either autologous or allogeneic cells. If cells to be used are the 
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differentiated progeny of iPS cells reprogrammed from the patient’s own cells, 
these cells are viewed as “autologous” cells. The likelihood of immune 
rejection towards them after transplantation will be significantly reduced. In 
the case that a human iPS bank consisting of various human leukocyte antigen 
(HLA) types is established, iPS cells selected from the cell bank can be used 
as an alternative to generate semi-allogeneic differentiated cells that share 
some of the HLA alleles with recipients. The third method of using iPS cells is 
to generate differentiated allogeneic cells suitable for applications that do not 
require the long-term survival of transplanted cells, such as when using stem 
cells as cellular vehicles for targeted cancer therapy. While long-term 
immunosuppressive treatment is required for many regenerative medicine 
applications of allogeneic stem/progenitor cells, it will not be necessary when 
iPS cell-derived cells are used as exogenous cellular vehicles for cancer 
treatment, since the application does not really require stem cell engraftment. 
Using allogeneic cells derived from iPS cells as cellular vehicles for 
cancer therapy can be justified for several reasons. Firstly, it is possible to use 
genetic engineering to introduce a therapeutic gene into iPS cells, in order to 
generate a master cell line for cell therapeutic production. Secondly, the 
allogeneic cell approach allows large-scale mass production of cell 
therapeutics, a prerequisite for widespread application of cell therapy suitable 
for repeated patient treatments. Large-scale mass production will also increase 
cost-effectiveness by reducing labor costs and simplifying the logistics of cell 
culture operations. In addition, it becomes possible to prepare cryopreserved 
derived cells as commercial products in ready-to-go format. Thirdly, the 
allogeneic cell approach allows standardized manufacture, which should be 
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helpful in eliminating variability in the quality of cellular products, thus 
facilitating reliable comparative analysis of clinical outcomes. 
Despite the advantages of iPS cells, more extensive studies need to be 
done to prove that the differentiated cells from iPS cells and hESCs are 
interchangeable. One concern about using iPS cells to derive downstream cells 
is the maintenance of genetic and epigenetic states of the iPS cells such as the 
methylation pattern. It has been shown that the reprogrammed stem cells carry 
an epigenetic memory of the original tissues which lingered even after the iPS 
cells had been differentiated into new tissues
147
. In addition to this, another 
important concern regarding the use of hPSCs derived cells is the ability of 
hPSCs to develop teratomas. This safety concern applies to iPSCs too, as they 
can also form teratomas
140
.  
2.4.2 Tumor tropism of iPS-EPCs 
Our biodistribution experiments have clearly demonstrated the tumor tropism 
of the generated iPS-EPCs. However, our study also showed that majority of 
intravenously injected iPS-EPCs were trapped in the lungs in the orthotopic 
breast cancer model, possibly due to the narrow diameters of lung capillaries. 
After initial pulmonary trapping, many intravenously injected cells tended to 
be re-distributed from the lungs to the liver and spleen.
 
Comparable results 
were shown by Wei et al., in which tail vein injections of mouse embryonic 
EPCs into C3H mice resulted in the injected cells being predominantly 
sequestered in the lung and spleen
85
. Our previous biodistribution studies 
using human neural stem cells (NSCs) also showed a similar cell distribution 
pattern
128
. This distribution pattern is useful for eliminating metastatic cancer 
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cells in the lungs, liver and spleen and has provided a rationale for us to test 
the therapeutic effects of intravenously injected iPS-EPCs in the breast cancer 
lung metastasis model in the current study. This cell distribution pattern, 
however, also emphasizes the importance of minimizing off-target transgene 
expression if the cell delivery aims to treat primary breast cancer.  
In the invasive 2M1 glioma model, we showed that EPCs can be 
incorporated into the 2M1 tumor blood vessels. These results corroborate the 
study by Moore et al. which demonstrated systemically transplanted cord 
blood-derived EPCs in vivo tropism for intracranial gliomas
148
. Furthermore, 
EPCs were also found in tumor satellites away from the primary tumor site, 
suggesting that there is potential for cell delivery of gene therapy to metastatic 
sites. 
2.4.3 Effect of iPS-EPCs in cancer growth and metastasis 
Circulating bone-marrow-derived EPCs might follow the gradients of growth 
factors and cytokines that are released into circulation by tumors and 
contribute to tumor neovascularization, tumor growth, and metastasis
149
. 
However, this contribution remains controversial, since the existence of these 
EPCs during tumor progression vascularization has been established in certain 
models and disproved in others, depending on the tested tumor models and 
methodologies
150
. NSCs have also been exploited as cellular vehicles in many 
preclinical and clinical studies for targeted delivery of therapeutic genes for 
cancer therapies
39, 128, 151
. However, our group has demonstrated that hESC-
derived NSCs suppress the maturation of DCs and impair the functional 
capacity of DCs to stimulate alloreactive T cells
152
. These immunosuppressive 
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effects exerted by stem cells will have a negative impact on cancer treatments 
when they are used as cellular gene therapy delivery vehicles. Thus, in this 
study, we also included iPS-NSCs alongside our iPS-EPCs to study the 
differences between different cellular vehicles. 
We did not observe any obvious contributions of iPS-EPCs and iPS-
NSCs to breast cancer growth and metastasis in both the primary and 
metastatic tumor models. Interestingly, in the lung metastatic cancer model, 
injection of fibroblasts alone resulted in an increased tumor volume at day 21, 
although there was no significant difference in animal survival by the end of 
the experiment. Carcinoma-associated fibroblasts (CAFs), the activated 
fibroblasts, are the primary type of host cells in tumor microenvironment. The 
origin of CAFs is not conclusively established and remains controversial
153
. 
Whether the systemically injected fibroblasts tested in the current study were 
recruited by the tumor and activated in situ to become CAFs is worth pursuing 
in future research. 
2.4.4 Immunotherapy of EPCs using CD40L  
To employ iPS-EPCs as donor cells to deliver the CD40L gene or other 
therapeutic genes for cancer therapy, it is essential that these cells can be 
genetically modified in a safe and effective way to carry therapeutic payloads 
of interest over the period of time crucial to the therapy. In the current study, 
we demonstrated for the first time that baculoviral vectors can be used for 
genetic modification of human EPCs to provide a window of transgene 
expression suitable for cancer therapy. Large cloning capacity, ease of virus 
production and low cytotoxicity to transduced cells are the obvious advantages 
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associated with the emergence of baculoviral vectors in the gene delivery 
field. Insect baculovirus also bypasses the risk of virus replication and 
potential viral infection in host cells, risks borne by conventionally-used 
animal viruses such as adenovirus, retrovirus and adeno-associated virus. The 
pre-existing host immune response against adenoviral vectors, a type of 
vectors commonly used for transient transgene expression, is another concern 
that restricts the use of these vectors
154, 155
. Unlike adenovirus, baculovirus is 
not targeted by pre-existing immunity in humans
156
.  
CD40L was used as a model therapeutic agent to test iPS-EPC-
mediated gene delivery. CD40L, also called CD154, is a 33-kDa type II 
membrane protein belonging to the TNF gene family and is mainly expressed 
on activated CD4
+
 T cells. It interacts with CD40 expressed on a wide range of 
antigen-presenting cells (APCs) including dendritic cells, macrophages, and B 
lymphocytes, as well as non-immune cells such as epithelial cells, endothelial 
cells and malignant cells
105
. CD40L-CD40 interaction induces activation in 
APCs in association with T cell receptor stimulation by MHC molecules on 
the APCs, ensuring the generation of antigen-specific cytotoxic T lymphocytes 
(CTLs). Increased antigen presentation by APCs can lead to increased 
cytokine production, expression of other co-stimulatory molecules, and 
induction of cytotoxicity. CD40L can also exert antitumor effects by inducing 
tumor cell apoptosis via autocrine/paracrine induction of death ligands such as 
TNFa, FasL, and TRAIL
105
. Local CD40L gene delivery to directly transduce 
tumor cells can mediate multiple antitumor effects, including the induction of 
T-cell responses, upregulation of TH1 cytokines and induction of apoptosis, 





Our results showed that CD40L delivered by systemically injected iPS-
EPCs could reduce the tumor burden and eventually prolong the survival of 
tumor-bearing animals. To test human EPCs, immunocompromised Balb/c 
nude mice were used to produce tumor models in the current study. This strain 
of mice lacks T cells, but still acquires B cells and innate immune cells such as 
NK cells and complement immune system. Thus, the upregulation of TH1 
cytokines and the induction of apoptosis, but not induction of T-cell responses, 
might play more important roles in the observed antitumor action. Our 
approach is different from the strategy of direct transduction of tumor cells 
with the CD40L gene, as it uses baculoviral CD40L transduction of iPS-EPCs 
and the tumor tropism property of the cells to activate a local CD40L-CD40 
interaction in tumors. This is most likely achieved through a bystander 
mechanism of intercellular transfer of the CD40L protein from donor iPS-
EPCs to tumor cells. It has been established that CD40L protein transfer to 




We also studied the therapeutic effect of EPCs expressing HSV-tk 
using the same settings. However, we found that the effect is less pronounced 
compared to EPCs that express CD40L as the therapeutic gene. This may be 
due to the multiple antitumor mechanisms that CD40L has. Besides, homed 
EPCs might trigger tumor growth until the suicide gene system is activated as 
the suicide gene needs time to kill using the bystander effect. Furthermore, the 
suicide gene vehicle has an inherent disadvantage in that it destroys itself, 
limiting the amount of time it has in which to work
99
. Due to these reasons, it 
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is possible that the therapeutic effects exerted by HSVtk cannot overcome the 
fast growing tumor mass and metastasis.   
We also investigated the therapeutic effect of a novel angiogenic 
inhibitor, Isthmin (ISM). This 60kD protein, which was first identified in the 
Xenopus brain, has been shown to inhibit endothelial cell (EC) capillary 
network formation on Matrigel and induce EC apoptosis
126, 127
. Although it has 
been shown that overexpression of ISM in mouse B16 melanoma resulted in 
inhibition of the tumor growth upon subcutaneous injection into the mice
126
, 
our results showed that ISM could not inhibit the growth of pre-established 
tumour in mice when delivered systematically. One plausible reason is that a 
high concentration of ISM may be needed to exert the antiangiogenic effect. 
When overexpressed in the tumor, the tumor angiogenesis is inhibited from 
the start, thus making a more distinct impact on tumor growth. In a pre-
established tumor, a higher concentration and more prolonged exposure of 
ISM may be required to exert the same effect. Moreover, studies have shown 
that only soluble ISM has antiangiogenic effects, whereas immobilized ISM 
loses its antiangiogenic function and instead promotes EC adhesion, survival 
and migration through avb5 integrin
127
. Further studies are needed to 
investigate whether the isthmin delivered by the EPCs are immobilized in the 
ECM of a tissue or soluble in circulation.   
2.4.5 Challenges and future direction 
In this study, while the term “iPS-EPC” was used for these iPS cell-derived 
cells, we do realize that the population could contain cells at different levels of 





 cells, can be added to remove relatively matured cells. 
For clinical applications, more robust and cost-effective cell expansion 
technologies will be required. In this aspect, expansion methods such as 
automated bioreactors and rotary culture machines hold promise for 
generating iPS cell derivatives in bulk
159
. 
An important concern regarding the use of therapeutic cells derived 
from iPS cells is the potential of the latter to form teratoma. Incomplete 
differentiation could bear a risk of teratoma development in mice or patients. 
Thus, an experiment to test teratoma formation in animal models after 
injection of iPS-EPCs can be performed to ensure the safety of this therapeutic 
mode.  
One issue that needs to be resolved is the degree of the EPCs tumor 
tissue selectivity, to reduce potential toxicity due to off-target organ failures. 
Several strategies can be used to enhance the tumor tissue-specific transgene 
expression for cancer gene therapy. A popular method is the use of tumor 
environment-specific promoters including hypoxia response elements, a 
proendothelin-1 promoter, or a survivin promoter
93, 160-162
. Given that the 
vesicular stomatitis virus glycoprotein (VSV-G) can promote the formation of 
multinucleated syncytia to kill cells in a pH-dependent manner, we have generated 
a VSV-G mutant that efficiently promotes syncytium formation at the tumor 
extracellular pH but not at pH 7.4
163
. Using transduced NSCs derived from iPS 
cells to deliver the VSV-G mutant into mice with metastatic breast cancers in 
the lung through tail vein injections, we observed tumor-selective killing 
without obvious toxicity to normal non-targeted organs.  We are also working 
92 
 
on the development of regulatory systems that regulate the transgene 
expression in the cellular vehicle in an inducible manner in response to tumor 
hypoxia. 
The transient gene expression mediated by baculovirus of non-
integrating nature has been noted to have limits to its efficacy in studies that 
require long-term transgene expression. One way to improve the survival rate 
of the animals is through multiple rounds of iPS-EPCs-CD40L injections. This 
way, the CD40L expression in the animal can be periodically boosted, which 
in turn will enhance the immune reaction against the tumor in the animals. 
Another way to overcome the limitation is by ensuring longer expression of 
the transgene in the iPS-EPCs. Our lab has developed several baculoviral 
transduction-based approaches using either recombinase-mediated cassette 
exchange (RMCE), zinc finger nuclease (ZFN) technology or transcription 
activator-like effector nuclease (TALEN) technology for site-specific 
integration, without random integration, of a transgene in human pluripotent 
cells 
98, 139, 164, 165
. We are in the midst of establishing iPS cell lines to achieve 
stable expression of transgenes in the differentiated progeny of the iPS cells, 
including EPCs. 
In conclusion, we have demonstrated the feasibility of generating EPCs 
from early-passage human iPS cells. We further showed the tumor tropism of 
the generated EPCs and the effectiveness of using intravenously injected EPCs to 
deliver CD40L to inhibit metastatic breast cancer growth in the lung, possibly 
through an intercellular transfer mechanism. The potential of this approach is 
not limited to metastatic breast cancer therapy but can likely be extended to 
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treat primary lung cancer and many other types of pulmonary metastases. In 
this chapter we demonstrated that an immune-modulatory gene, CD40L, could 
result in cancer therapeutic effects after being delivered via EPCs. In the next 














CHAPTER III: TARGETED CANCER THERAPY USING 
CYTOTOXIC T LYMPHOCYTES ACTIVATED BY 






3.1.1 Cancer stem cells 
Cancer stem cells (CSCs) are a small population of cells in the tumor that 





have shown that CSCs express similar gene expression as normal embryonic 
stem cells, including STAT3, Oct3/4 and nanog, which explains their similar 
properties in self-renewal and differentiation properties
166, 168
. However, 
isolation and further observations have been hampered by the small number of 
cells since CSCs are a minority population just like normal stem cells. 
Efficient methods to enrich this cell population would alleviate this problem 
significantly. The non-adherent, 3-D tumor spheres culture method and 
reprogramming approach have been shown to enrich CSCs in vitro
169, 170
.  
Taking advantage of sphere culture, surface markers analyses, 
functional studies in vitro (spheres formation and in vitro differentiation 
assays) and in vivo tumor initiation models, the existence of CSCs has been 
demonstrated in several cancers including breast, ovarian and prostate cancers, 
melanomas, gliomas, head and neck squamous carcinoma and many more
166, 
167, 171
. The tumor-initiating cells were first isolated from a breast cancer by 





well-studied cell surface markers for CSCs include CD133, epithelial cell 




The four factors (Oct4, Sox2, Klf4 and Nanog) in 
Takahashi/Yamanaka reprogramming iPS cocktails are oncogenes by 
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definition, and their over-expression has been associated with cancers
173-175
. 
Thus, many researchers have turned their focus to the use of reprogramming 
approach to enrich CSCs by introducing at least one of these factors
170, 175
. 
Hypoxic conditions have also been utilized to reprogram glioblastoma cells 
into CSC-like cells
176
. The acquired stem cell phenotypes have been shown to 
be more tumorigenic and resistant to chemotherapeutic drugs
170, 176
. Thus, 
these cells are very promising novel targets for tumor therapy.    
3.1.2 Objective 
DC-based vaccines have been perceived as a powerful immunotherapy 
approach against cancer. This is because DCs hold a very important place in 
the stimulation of immune responses, especially CTLs, powerful immune 
killer cells to eradicate cancer cells. Depending on the antigens loaded onto 
and presented by the DCs, T cells will target populations of cells that express 
them. Thus, the choice of target antigen is crucial. Conventional chemotherapy 
and radiation therapy, which target rapidly growing tumor cells, are incapable 
of destroying the CSCs
166, 167, 170
. The quiescent state of CSCs, efficient 
mechanisms of DNA repair, intrinsic expression of anti-apoptotic mechanisms 
and expression of efflux transporters are some strategies to build this 
resistance
166, 167
. The survival of CSCs explains the tumor recurrence in 
patients. Therefore, CSCs emerge as a promising therapeutic target for 
anticancer therapies.  
Our lab has successfully developed several baculoviral transduction-
based approaches using zinc finger nuclease (ZFN) technology for site-
specific integration, without random integration, of reprogramming factor 
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genes to facilitate the generation of human pluripotent cells
177
. Zinc Finger 
Nucleases (ZFNs) technology facilitates site-specific integration of the 
transgene encoding the four reprogramming factors at adeno-associated virus 
type 2 target region (AAVS1 locus) on chromosome 19. This site is known as 
a ‘safe-harbor’ human genomic site for exogenous DNA insertion98, 139. Using 
the same method, we have also successfully reprogrammed various cancer cell 
lines such as glioma and colorectal cancer (CRC) into CSC-like cell states. 
Our lab showed that CRC-CSC-like possess higher propensities to form 
tumorspheres in vitro as compared to wild-type CRC. Moreover they express 
significantly higher CSC markers such as CD133 and CD24 (data not shown, 
performed by lab members).  
The conceptual flow of the project can be seen in Figure 3.1. Whole 
tumor lysates were produced from the CRC and glioma CSC-like cells. We 
then used these whole lysate antigens to pulse PBMC-derived DCs. We 
believed that the four reprogramming factors are also included in the lysate 
and we hypothesized that these antigens can be presented by DCs to the T 
cells and subsequently results in the activation of CTL which can target the 
CSCs population. 
The key factors in this project were the viability of the DCs used and 
the proper assessment of the T cells activation. In the first part of our study, 
we focused on producing a sufficient quantity of highly functional DCs from 
PBMCs. We relied on flow cytometry which has been widely used to 
characterize the PBMC-derived DCs.  
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In the second part, T naïve cells isolation and characterization were 
carried out. In this project, naïve T cells were isolated and memory T cells 
were depleted. This is because memory T cells have been shown to have lower 
activation threshold, thus can result in non-specific expansion
178
. Flow 
cytometry to characterize the co-stimulatory as well as inhibitory markers of T 
cells will be tested.  
In the last section, the level of CTL activity in terms of functionality 
and specificity will be examined. A functional assessment of T cells in terms 
of the production of cytokines such as IFNγ will be performed. The ELISPOT 
assay is a highly sensitive antibody-capture-based method for enumerating 
specific T cells that can secrete cytokines. Thus, this technique will be adopted 
in this project. We aimed to test whether IFNγ production by the T cells was 
specific to the target cells that expressed the CSC-like antigens. Ultimately, 
we postulated that a CSC-specific T cell response from DC vaccination using 
CSC-like antigens can be generated.   
 
Figure 3.1. Antigen presentation and CTL activation. CSC-like antigens 
presentation by the DCs leads to CTL activation and eventually targeting of cells 








3.2 Material and methods 
3.2.1 DCs and naïve T cells derivation from PBMC 
DCs and naïve T cells were derived from human peripheral blood 
mononuclear cells (PBMCs), both HLA-A2 positive and negative (AllCells, 
Stemcell Technologies Inc) based on previous studies 
178
. To generate DCs, 
1×10
8
 human PBMCs were seeded onto a T-175 cm
2
 flask and incubated for 3 
h at 37°C in Cellgro® DC medium (CellGenix, GmbH, Freiburg, Germany) 
supplemented with 5% human AB serum and 1×P/S. After 3 h, 20 ml of DC 
differentiation medium (Cellgro DC medium + 5% human serum + 1×P/S + 
50 ng/ml GM-CSF + 100 ng/ml IL4) was added to the attached cells. Half of 
the medium was changed 2 days later. As most of the cells have detached at 
this point, the medium change was performed as follows: take out 10 ml 
medium, spin down 300 g for 5 min, re-suspend with 10 ml fresh medium and 
put the re-suspended cells back to the flask. On day 4, the immature DCs were 
collected for DC pulsing and maturation or for DC characterization by flow 
cytometry. Meanwhile, the non-attached cells were collected and cultured 
separately in Cellgro medium as above with additional supplementation of IL7 






 naïve T 
cell population from the PBMC was carried out via MACS using CD8, 
CD45RO and CD57 microbead kit (Miltenyi Biotec). All the cytokines were 
purchased from Peprotech or Miltenyi Biotec. 
3.2.2 Tumor lysate preparation  
To prepare for the tumor lysate, wild type and 4F-BV-ZFN reprogrammed 





 cells/ml in PBS. The cells were then subjected to six 
cycles of freeze-thaw treatment (freezing with liquid nitrogen for 20 min and 
thawing 5 min at 37
o
C water bath) to produce the whole tumor lysate.  
3.2.3 DCs pulsing with tumor lysate and maturation 
The dendritic cells were harvested and separated into different groups: DC 
pulsed with 4F-BV-ZFN-tumor, DCs pulsed with WT tumor and unpulsed 
DCs. The DCs were then mixed with the whole tumor lysates with a cell ratio 
of 1:1 according to the groupings. After a 16 h incubation, 60 EU/ml of LPS 
(Escherichia coli; Sigma) and 2000 IU/ml of IFNγ were added into the culture 
to stimulate DC maturation for a further 16 h at 37°C, 5% CO2.   
3.2.4 CTL stimulation and expansion 
The naïve T cells were then primed with the pulsed and matured DCs at 1:4 
DC: T cell ratio. Prior to the priming, the DCs were subjected to mitomycin C 
treatment in order to inhibit cell proliferation including the contaminants NK 
cells and monocytes. The cell mixtures were cultured and expanded in a 
Cellgro medium supplemented with 5% human serum, 1×P/S, IL21 (30 
ng/ml), IL7 (5 ng/ml) and IL15 (5 ng/ml) for 10 – 11 days.  
3.2.5 Flow cytometry 
For DCs characterization, flow cytometric analyses were performed using the 
antibodies: CD11c, CD86, DC-SIGN, CD80, CD40, CD83 and HLA-DR (BD 
Biosciences). For T cell characterization flow cytometric analyses were 
performed using these antibodies: CD8, CD4, CD62L, CCR7, CD27, CD28, 
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CD45RO, CD45RA, CD57, CD25, CD127, HLA-ABC and HLA-A2 (BD 
Biosciences). 
3.2.6 ELISPOT 
To detect the cytokine (IFNγ) production by the stimulated CTL, we 
performed ELISPOT assay (MabTech AB, Sweden). As target cells, T2 cells 
or 0.05% glutaraldehyde-fixed DCs were used when the PBMCs were HLA-
A2 positive or HLA-A2 negative respectively. The pulsed or unpulsed DCs 
were fixed with 0.05% glutaraldehyde for 30 seconds. The T2 cells were 
incubated with 3 µg/ml Oct4 or EGFP peptide at room temperature for 3 h.  
The T responder cells were then co-cultured with fixed DCs or T2 
target cells at responder: target = 10: 1 in Cellgro medium using 96-well U-
bottom plates. After 24 h of incubation, the cells were then transferred to the 
antibody-coated microtiter plates. The antigen-specific T cells were detected 
by the sequential addition of biotinylated mouse anti-human IFNγ (2 h at room 
temperature), five washes with DPBS, alkaline phosphatase-conjugated 
streptavidin (1 h at room temperature), five further washes with DPBS, and 
substrates for streptavidin. Spots were then developed and stopped after 10 
min by washing vigorously with tap water. The spots corresponding to the 
IFNγ producing cells were then scanned and analyzed using an automatic plate 
reader CTL – Biospot® S6 UV analyzer (Cellular Technology Limited, Ohio, 





3.2.7 Statistical analyses 
All data are represented as mean ±SD. The statistical significance of 
differences was determined by one-way ANOVA followed by the Holm-Sidak 
method for pairwise multiple comparison tests. A p value of <0.05 was 
considered to be statistically significant. 
3.3 Results 
3.3.1 DCs derivation and characterization 
The production of sufficient and functional DCs is crucial in DC-based cancer 
immunotherapy. In this study, DCs were derived from PBMCs, with Figure 
3.2A showing the schematic diagram of the protocol. The PBMCs were 
seeded and incubated for 3 h. The attached cells were the monocytes which 
will be differentiated to DCs whereas the floating cells were collected for T 
naïve cell sorting. To differentiate DCs from PBMCs, IL4 and GM-CSF were 
added to the differentiation medium. Thereafter, the attached monocyte-DCs 
become floating or loosely attached DCs (Fig. 3.2B, C). Furthermore, we 
observed morphological changes in the cells over time. In the beginning, most 
of the cells are spherical. However, at day 4, most of the cells are irregular-
shaped with dendritic arms starting to develop (Fig. 3.2C). We can produce up 
to 8×10
6
 DCs from 1×10
8
 PBMCs. 
Our lab has established the CSC-like cells by reprogramming cancer 
cells such as colorectal cancer (CRC) and U87 glioma cells by using the 
baculoviral vector expressing four reprogramming factors (Oct4, Sox2, Klf4 
and C-Myc), zinc finger and EGFP (4F-ZF-EGFP). The increased expression 
of the four factors has been analysed using RT-PCR, real time PCR and 
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western blot (data not shown). These reprogrammed cancer cells were used to 
make the cell lysates. CRC and U87 wild type cells were used as controls, as 
well as PBS as unpulsed control. After pulsing with the lysates, the cells were 
subjected to IFNγ and LPS in order to induce the DC maturation. Interestingly, 
after pulsing followed by maturation, most of the DCs became tightly attached 
cells (Fig. 3.2D). 
 
 
Figure 3.2. Dendritic Cells and T cells derivation from PBMC. A. DCs 
differentiation and naïve T cells selection from human PBMC. B. Differentiated DCs 




 Evaluation of immunological surface markers is a common yet 
important method to evaluate the identity and functionality of the DCs. At 
first, we performed flow cytometry of the whole population of PBMCs to 
examine the profile of the cells available (Fig. 3.3). We could see that all the 
cells were positive for CD45 marker which is the leukocyte common antigen 
(99.95%). High expressions of lymphocytes markers were found. The cells 
were positive for cytotoxic and helper T cells markers, CD8 (34.98%) and 
CD4 (50.35%) respectively. They were also positive for other lymphocytes 
markers CD3 (80.31%) and CD7 (73.24%). HSC marker CD34 was negative 
(0.2%) but 75.34% of the cells were positive for CD31 marker. Furthermore, a 
small but distinct population of the PBMC expressed NK cell markers: CD16 
(4.52%), CD94 (3.02%) and CD56 (0.67%). 
We then evaluated the expression of DC markers in the immature and 
mature DCs (Fig. 3.4). The immature DCs were positive for DC markers such 
as CD11c, CD86 and DC-SIGN with expression of more than 90%. However, 
the expression of CD40 was dimmed (48.97%) and no expression of CD83 
was detected (0.96%). Upon maturation, the expression of CD83 and CD40 
increased considerably, from 0.96% to 98.76% and from 48.97% to 99.30% 
respectively. Furthermore, the expressions of the other DC markers were 
maintained at high levels. In addition to this, the DCs were positive for MHC I 
and II (HLA-ABC & HLA-DR), with the percentage expression of 99.93% 




Figure 3.3. Characterization of PBMCs by flow cytometry. The cells are positive 
for cytotoxic and helper T cells markers, CD8 (34.98%) and CD4 (50.35%) 
respectively. They are also positive for other lymphocytes markers CD3 (80.31%) 
and CD7 (73.24%). All the cells are positive for leukocyte common antigen, CD45. 
The cells are negative for HSC marker CD34 (0.2%) but 75.34% positive for CD31 
marker. Small population of the PBMC expressed NK cell markers: CD16 (4.52%), 




Figure 3.4. Characterization of DCs by flow cytometry before and after pulsing 
and maturation. The DCs are positive for MHC I and II (HLA-ABC & HLA-DR). 
The DCs are also positive for DC markers such as CD11c, CD86, DC-SIGN with 
expression of more than 90%. Upon maturation, the expression of CD83 and CD40 




3.3.2 Naïve T cells selection and characterization 
We investigated whether tumor antigen-specific CTL can be mounted from the 
naïve T cells. Thus, we selected the naïve T cells from the PBMC derived 
lymphocytes repertoire by using MACS (Fig. 3.2A). First we selected the 
CD8
+





 memory T cells. From the flow cytometry 
results, we observed that the proportion of CD8
+
 cells out of the whole 
PBMC-lymphocytes was approximately 30% on average (28.3% as shown in 
Figure 3.5A). After cell sorting, the purity of the CD8
+
 cells reached 98.2%. 
We tested the memory T cell markers and the results showed that 28.57% of 
the cells expressed CD45RO (Fig. 3.5A). The CD57 memory T marker 
expression was lower than that of CD45RO, 9.37% (Fig. 3.5A). However, 
after depletion of memory T cells by magnetic sorting, expression of these 
markers was not detected (Fig 3.5A). On average, we obtained 1×10
7
 naïve T 
cells from 1×10
8
 PBMCs. We also checked the expressions of T cell co-
stimulatory molecules such as CD62L, CCR7, CD27 and CD28 before and 
after priming with the DCs (Fig. 3.5B). All markers were expressed before 
and after DC activation. 
Tregs inhibit the CTL activation and antitumor effect. Thus, we 
checked the expression of Treg markers in the sorted naïve T cells population. 






 cells. From 
Figure 3.5C, we observed that our sorted T cells were negative for Treg 
markers as the expression of CD4 marker was very low (0.87%). Moreover, 
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the CD25 marker albeit expressed at 9.66%, showed a dimmed expression. In 
addition, almost all of the cells (97.56%) were positive for CD127. 
 
Figure 3.5. Characterization of CTL by flow cytometry before and after priming 
with DCs. A. Naïve T cells characterization before and after sorting. CD8 expression 
before sorting was 28.3% and after sorting, the purity of CD8
+
 cells was 98.2%. The 
expression of memory T cells markers was 28.57 and 9.37% for CD45RO and CD57 
respectively. After depletion of memory T cells, the memory T cells markers 
expression were very low (1.1%). B. Expression of costimulatory molecules before 
and after DC priming as shown by flow cytometry. C. Flow cytometry for Treg 
markers: CD4 (0.87%), CD25 (9.66%) and CD127 (97.56%).  




3.3.3 IFNγ production of CTL activated by CSC-like-CRC-pulsed DC 
After the activation and expansion period, the T cells were mixed with the 
target cells and their IFNγ production was evaluated. Figure 3.6 shows the 
cytokine production by CTL activated by CSC-like CRC lysate-pulsed DCs. 
The groupings of the cells are shown in Table 3.1. T2 cells were used as the 
target cells as the PBMCs were HLA-A2 positive. These cells were pulsed 
with Oct4, EGFP peptides or PBS as control. T2 target cells alone without the 
addition of effector T cells were used as a negative control, as these T2 cells 
should not produce IFNγ. As a background control, spontaneous production of 
IFNγ from naïve T cells alone was measured. On the other hand, the cytokine 
productions from naïve T cells which have been activated by CD3 antibody 
were used as positive control.  
As expected, T2 cells alone did not release any IFNγ, but the T cells 
alone spontaneously released IFNγ at low levels with an average of 61.67 T 
cells/ 50,000 cells. More T cells produced IFNγ after activation by CD3 
antibody, 96.5 T cells/50,000 cells. Production of IFNγ is the highest in CTLs 
which have been primed with DCs pulsed with 4F-ZF-EGFP CRC cells mixed 
with T2 target cells pulsed with Oct4 or EGFP. The ANOVA and the Holm-
Sidak pairwise comparison tests showed that the differences between these 
two groups are not significant. However, when either of this group was 
compared to the rest of the groups, then the differences are very significant.  
Furthermore, statistical tests comparing the WT-T, UP-T, T alone and 3.11-T-




Table 3.1. Grouping of ELISPOT for T cells after activation by DCs pulsed with 




Figure 3.6. Production of IFNγ by CTL after activation by DCs pulsed with 
reprogrammed CRC cell lysate. Production of IFNγ is the highest in T cells which 
have been primed with DC pulsed with 4F-ZF-EGFP CRC cells mixed with T2 target 
cells pulsed with Oct4 or EGFP (Anova P value =˂0.001).  
 
3.3.4 IFNγ production of CTL activated by CSC-like-glioma-pulsed DC 
We have also established CSC-like glioma cells by transducing U87 glioma 
cells with 4F-EGFP-ZF baculovirus. We then utilized this CSC-like glioma to 
produce a cell lysate that contains all the tumor antigens including the proteins 
of the four factors. Subsequently, this lysate was used to pulse the DCs which 
111 
 
in turn were used to prime the autologous naïve T cells. We then examined the 
production of IFNγ by these activated CTLs upon mixing with target cells. As 
the PBMCs from which the DCs and T cells were derived from are HLA-A2 
negative, peptide pulsed T2 cells were not used as the target cells. Instead, 
dendritic cells pulsed with the CSC-like U87 lysate and subsequently fixed by 
glutaraldehyde were used as target cells. The groupings of the cells were 
shown in Table 3.2.  
As shown in Figure 3.7, IFNγ production was the highest in the T cells 
group that had been pulsed with DCs and mixed with the glutaraldehyde-fixed 
pulsed-DC. The ANOVA and Holm-Sidak tests showed a significant 
difference between this group and the rest of the groups. On the other hand, 
when comparing the other groups, no statistically significant differences were 
observed.     
Table 3.2. Grouping of ELISPOT for T cells after activation by DCs pulsed with U87 





Figure 3.7. Production of IFNγ by CTL after activation by DCs pulsed with 
reprogrammed glioma cell lysate. Production of IFNγ is the highest in T cells 
which have been primed with DC pulsed with 4F-ZF-EGFP U87 glioma cell lysate 
mixed with fixed-DC target cells pulsed with the lysate; ANOVA P = <0.001.  
 
3.4 Discussion 
3.4.1 DC differentiation and characterization 
Dendritic cells are the center of innate and adaptive immune axes. Numerous 
studies have been done to investigate their derivation, differentiation and 
functions in immunology and immunotherapies. Human DCs can be 
differentiated from various cellular sources, such as CD34
+
 progenitor cells 
from bone marrow, cord blood and pluripotent stem cells, or from circulating 
monocytes from PBMC, and using various protocols and cytokine cocktails to 
skew the differentiation towards DCs
178-181
. The most widely used DCs for 




In this study, we adopted a method from the study by Wolfl et al.
178
 to 
generate both DCs and naïve T cells from PBMCs. The profiles of the whole 
PBMC we used are similar to previous data using freshly isolated human 





differences can be due to batch-to-batch variations of the PBMCs used. 
Likewise, the derived DCs are comparable to previous reports which used 
GM-CSF and IL4 supplements
179, 184-186
. Lysate pulsing represents a 
maturation inducer for the DCs. Moreover, this maturation process was further 
supported by LPS and IFNγ supplementations. Other maturation conditions 
have been described by others, such as the use of TNFα. However, the 
combination of LPS and IFNγ has been shown to stimulate IL12 production by 
the DCs, which is necessary for skewing towards a Th1 activation and 
augmenting CTL responses
6, 178, 179
. Indeed, upon pulsing with lysate, there 
was upregulation in CD83 and CD40 DC maturation markers expression, 
comparable to previous studies
179, 185, 186
.The upregulation of these co-
stimulatory molecules is necessary to enhance the capacity for antigen 
presentation and T cell stimulation, which most probably occurred at the cost 
of antigen uptake capacity
4
. Moreover, the DCs were positive for MHC I 
which is crucial for antigen presentation process. In addition to this, 
morphological changes were also detected. The mature DCs developed long 
arms of dendrites as opposed to small irregular shaped appendages on the 
immature ones. These long dendritic processes have been known to increase 
the chance of T capture and interaction
34
.      
Thus, using this protocol and based on the surface markers detection, 
we have generated sufficient numbers of functional DCs. These lysate-pulsed-
DCs were used to prime the naïve T cells. Aside from detection of surface 
markers, DCs can be characterized by their phagocytic capability (immature 
state) as well as their capacity to produce cytokines (mature state) such as 
IL12, IL6. These are areas that we can explore further.  
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3.4.2 Activated CTLs display appropriate co-stimulatory molecules and 
antigen-specific targeting 
Naïve T cells are T cells that have not come across antigen activation. Once 
stimulated, these cells will differentiate into CTLs and memory T cells 
although the exact process of differentiation has not been elucidated yet
21
. The 
memory T cells are responsible for generating responses if the same antigen is 
detected again. When this happens, the duration of the immune response 
mounted is shorter as memory T cells have a lower activation threshold
178
. 
This is the reason why these cells need to be depleted. Similar to what was 
reported by Wolfl et al., non-specific T activation shown by higher variations 
amongst the elispot wells were detected when no memory T cell depletion was 
performed. 
The flow cytometry results of our isolated naïve T cells were 
comparable with results by Wolfl et al
178
. We observed that the naïve T cells 
could not survive past 10 days without stimulation by DCs. Interestingly, the 
survival of the cells improved greatly when no sorting was carried out. With 
this in mind, we performed sorting just prior to DC pulsing to minimize the T 
cell deaths. This implies that CD4
+
 cells support the survival of the CD8
+
 
naïve T cells. This may have great implications for adoptive T cell therapy. 
While it is very tempting to select only CD8
+
 T cells, exclusion of other 
subtypes of T cells may lead to deleterious effects for the T cells.  
As mentioned in Chapter I, antigen recognition alone is not sufficient 
for T cell activation. Interactions of co-stimulatory molecules on the T cell 
surface are critical for T cell survival and functions. Our flow results show that 
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our T cells maintained the expressions of the necessary co-stimulatory 
molecules comparable to previous findings
178, 183
. CD28, as mentioned, is 
needed to activate the CTLs via amplification of the signals from TCR. 
Moreover, CD28 stimulation also maintains T cell telomeric length which may 
improve their survival
21
. CD27, on the other hand, has been shown to support 
antigen specific expansion of naïve T cells and to complement CD28 
activity
187, 188




Monitoring chemokine receptor expression provides information 
regarding the status of T cells. After maturation, there seemed to be a 
downregulation of CCR7 expression, but not CD62L. Although this result is 
not indicated in Wolfl’s study, Dumortier et al. demonstrated the 
downregulation of both CCR7 and CD62L expression on T cells after LPS-
matured DCs priming. Both CD62L and CCR7 are lymph node homing 
receptors
6, 178, 191, 192
. By downregulating these markers, the T cells possess 
migratory capacity towards the target site
192-194
. As to why the downregulation 
was only detected in CCR7 but not CD62L in our case, the reason is unclear 
and requires more investigations.  
While CD8
+
 cells represent the CTLs which are involved in the tumor 
killing, the CD4
+
 T lineages are more complex. They comprise of T helpers 
(Th1 and Th2) which are important in assisting antibodies production by B 
cell and T cells proliferation through cytokine signaling. However, a different 
subpopulation of CD4
+
 named Tregs has been known to attenuate immune 
response. Thus, it is important to exclude this subpopulation of cells from the 
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activated CTLs. Treg cells make up 5-10% of naïve CD4
+
 T cells in the 
periphery
36
. By the end of the expansion phase, the expression of Treg 
markers on the T cell population was low; hence we expected little inhibition 
in CTL activity. 
The main cytolytic components from CTL are granzyme B and IFNγ. 
We have shown that the production of IFNγ is the highest on the target cells 
that express the antigen (T2 pulsed with Oct4 or lysate-pulsed-DCs fixed with 
glutaraldehyde). Therefore, based on the flow cytometric analyses and the 
ELISPOT results of the activated CTLs, we have demonstrated that the DCs 
pulsed with CSC-like cells antigens can stimulate specific CTL responses. 
Although these results are still at a preliminary stage, the potential of CTLs 
targeting CSC population could already be perceived.  
3.5 Future Direction 
As this is an ongoing project, there are several future works which need to be 
tackled. We are in the midst of testing the antigen-specificity targeting of 
CTLs by investigating granzyme B production of the cells. Moreover, we will 
also assess the CTLs killing effect using the CSC-like cells as well as primary 
tumor cells as the target cells, to verify this concept under more practical 
conditions in a preclinical experimental setting. In addition to this, we are 
eager to evaluate the CSC-like targeting using DC-based vaccine approach in 
other cancer lines which have been reprogrammed in our lab (for example, 
melanoma).  
The limitation in the number of monocytes that can be obtained from 
PBMCs and the variability of DC-differentiation potential from different 
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patients/donors lead to a demand for a better source of DCs for vaccination 
purposes. An alternative approach to this is the use of human iPS cells as an 
unlimited source to generate human DCs of consistent quality
195, 196
. As 
already discussed in the previous chapter, the use of iPS cells has many 
advantages, including ease of genetic engineering and the feasibility of large-
scale mass production of cell therapeutics. An especially fascinating direction 
is the possibility of generating human iPS banks with various human HLA 
types. This way, donor iPS cells selected from the cell bank can be matched 
with the HLA alleles of the recipients and used to produce semi-allogeneic 
differentiated DC vaccines.  
We have demonstrated that the combination of baculoviral vector and 
zinc finger nucleases technologies can be used to introduce stably site-specific 
integration of transgene
164, 165, 177
. Thus, using this method, we can overexpress 
tumor antigenic genes or DC activation/co-stimulatory molecules into the iPS 
cells, then differentiate the iPS into the DCs. The DCs expressing the antigens 
could then be used to activate CTLs responses. Our lab has also shown that 
hESCs stably modified with CD1d (a glycolipid MHC-related molecule
197
) 
gene may serve as a convenient, unlimited and competent DC source for iNKT 
cell activation, a unique subpopulation of lymphocytes which has the ability to 
lyse iNKT cell-sensitive tumor cells 
180, 198, 199
.  However, the safety of viral 
vectors has always been one significant problem of DNA-based DCs vaccines. 
By using site-specific integration into the AAVS1 site, the ‘safe-harbor’ 
human genomic site for exogenous DNA insertion, this problem can be 
circumvented.    
118 
 
Another interesting approach will be the use of iPS cells to generate 
activated T cells, thus bypassing the requirement of DCs stimulation. As 
mentioned above, genetic modification of T cells through tumor antigen-
specific TCR gene transfer or development of chimeric antigen receptor 
(CAR) T cells for adoptive therapy purpose also represents encouraging 
modalities in immunotherapy. One possibility is to generate genetically 
modified iPS cells which can be used as a master cell line to produce a 
sufficient amount of active CTLs for cancer therapy.  
To summarize, the DCs that have been loaded with CSC-like tumor 
lysate were able to activate CTLs. Subsequently the activated CTLs could 
specifically target the cells expressing the CSC-related antigens, which are the 
reprogramming factors used to enrich the CSC population. We believe that our 
approach in targeting CSCs via immunotherapy would be profoundly valuable 
in clinics. If it is used in combination with other therapies that target the bulk 
of tumor mass, such as surgical resection, chemotherapy or radiotherapy, then 

















In the preceding chapters, we have described the intricate mechanisms of our 
in-built immune system for fighting against cancerous cells. Elaborate 
interplays among innate and adaptive immune effectors are necessary to 
recognize and eventually eradicate the tumor cells. The innate immune system 
is fast in responding against cancer, with the killing effect mainly performed 
by NK cells. The other components of innate effectors, the APCs (dendritic 
cells and macrophages) are responsible for relaying the ‘danger signal’ to the 
adaptive arms of the immune system. The main killer of the tumor cells is the 
CTL. However, their survival and activities depend on the other adaptive 
immune cell populations, the helper T cells. The helper T cells produce 
cytokines and activate B cells to produce antibodies against tumor cells. When 
all the parts are functional, tumor eradication will ensue.   
Unfortunately, in cancer patients, the tumor cells have evolved to 
evade the immune system, or worse, to impair the immune mechanisms. This 
is the reason why cancer immunotherapy holds great potential in the clinics, 
by providing repair of or a new source of missing immune effectors. In the 
subsequent chapters, we adopted two approaches of immunotherapies: the 
stem cell- and DC- based therapies.    
In chapter 2, we experimented with cancer immune gene therapy by 
utilizing the CD40L gene delivered using iPS-EPCs to treat lung metastatic 
mice cancer model. We have shown that human pluripotent stem cells, hESC 
and iPS cells could serve as unlimited sources for the production of EPCs. We 
further showed the tumor tropism of the generated hPSCs-EPCs in different 
animal models: 4T1 mammary pad and lung metastatic models as well as 
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intracranial glioma model. Moreover, our findings add more value to 
baculovirus as a means to genetically modify mammalian cells effectively 
because we showed the efficient genetic modification of hPSCs-EPCs. 
Most importantly, we demonstrated the capability of EPCs to be an 
excellent cellular vehicle for cancer gene therapy. The intravenously injected 
EPCs can deliver CD40L to inhibit metastatic breast cancer growth in the lung 
and prolong the survival of tumor-bearing mice, possibly through an 
intercellular transfer mechanism. Interestingly, compared to other therapeutic 
genes (HSV-tk and isthmin), CD40L has a more effective therapeutic effect 
against the fast growing 4T1 metastatic breast cancer cells in an 
immunodeficient mice model, which may be due to the multiple antitumor 
effects possessed by CD40L. These effects include upregulation of TH1 
cytokines, NK cell activation, antibodies production and apoptosis. The exact 
mechanism of each effect is beyond this scope of study and will require 
further investigations to be unraveled. The inherent tumor tropism of EPCs 
combined with the immuno-modulation capacities of CD40L provide 
synergistic antitumor effects which are not only limited to metastatic breast 
cancer therapy but can potentially be extended to treat primary lung cancer 
and many other types of pulmonary metastases.  
 In Chapter 3, we adopted the DC-based vaccine to target cancer stem 
cell populations. As most of the available cancer treatments have been shown 
to spare CSCs population, these cells are capable of reestablishing tumor 
mass, resulting in the tumor recurrence in patients. Our lab has established 
reprogrammed human glioma and colorectal cancer CSC-like cells by utilizing 
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the baculovirus zinc-finger technology. We used whole cell tumor lysate 
generated via free-thaw-cycles of these enriched CSCs as a source of tumor 
associated antigens.  
The crucial factor in this project is to produce sufficient viable and 
fully functional DCs which can present the tumor associated antigens into the 
T cells. We showed that we could obtain sufficient functional DCs which 
expressed MHC I and co-stimulatory markers such as CD86, CD83 and CD40 
which are important for the antigen presentation process. Upon pulsing with 
the CSC-like cell lysate, these DCs were capable of stimulating naïve T cells 
into CTLs. The stimulated CTLs were capable of producing IFNγ cytokine. 
Moreover, the highest cytokine production is observed in target cells that 
expressed the tumor associated antigens. Thus, in this study we have 
developed a DC-based immunotherapy approach which targets the CSC-like 
cell population. This CSC-targeting DC-based vaccine approach is not limited 
only to glioma and CRC, which makes it more promising for clinical 
applications. We believe that in combination with other therapies that target 
the bulk of tumor mass, such as surgical resection, chemotherapy or 
radiotherapy, it is possible to achieve tumor eradication.  
Overall, our work has emphasized the importance of immunotherapy in 
the field of cancer research. By stimulating the patient’s own immune system, 
be it by delivering therapeutic agents using stem cells or vaccination via tumor 
antigen-loaded dendritic cells, tumor development can be abrogated. We 
believe that our concepts and findings are of substantial translational potency. 
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Furthermore, we expect this work to spur further studies pertaining to the 
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Supplementary figure 1. iPS-EPCs tumor tropism to 2M1 glioma intracranial 
model. A. Schematic diagram of injection and location of the cells. Injection was 
performed 2mm right of bregma point. B-E. Primary DiO-labeled 2M1 tumor mass 
infiltrated by DiI-labeled EPCs. F-I.  iPS-EPCs can be observed at 2M1 secondary 
tumor site. 
